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ABSTRACT 
Introduction: Androgen Insensitivity Syndrome (AIS) is an X-linked disorder 
caused by mutations in the androgen receptor (AR) gene. The phenotype is 
variable and ranges from a complete feminine syndrome to simple gynecomastia. 
The phenotypes are described in terms of complete, partial and mild forms (CAIS, 
PAIS and MAIS). We describe novel and previously reported (recurrent) 
mutations in the AR gene for a family in which segregation of breast cancer (BC) 
and gynecomastia/MAIS is present. Methods: We studied a family of 16 
members spanning four generations. Based on the presentation of symptoms, the 
family was divided into affected, unaffected, and control groups. Seven patients 
(six males diagnosed with MAIS and one female diagnosed with BC) formed the 
affected group, four genetically related individuals (two males and two females) 
formed the unaffected group and five genetically unrelated family members (one 
male and four females) served as controls. In each of these individuals, PCR 
amplification, cloning and the sequencing of exon 1 were carried out. Exons 2-8 
were sequenced directly after PCR amplification. Exon 1 (CAG)n and (GGN)n 
repeats were classified according to their length: short (S) (n<23), long (L) (n>23) 
and wild type (WT) (n=23). Results: Part 1-The (CAG)n repeats varied among 
individuals and generations. In the 2nd generation, the unaffected male was S and 
the control female was WT. In the 3rd generation, three affected males were S, 2 
of the controls were WT, one control was L and the other S. In the 4th generation, 
the 4 affected individuals were L, 1 of the unaffected was WT and the other 2 
unaffected were L. Part 2- The (GGN)n variations also differed among 
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individuals and generations. In the 2nd generation, the unaffected male and the 
control were S. In the 3rd generation, all three affected family members were S 
and among the controls, 1 was WT, 1 was L and 2 were S. In the 4th generation, 
3 of the affected were S and one was WT and among the 3 unaffected, 2 were S 
and one was WT. Part 3- 30 unreported (novel) mutations as well as 13 recurrent 
(previously reported) mutations in exon 1 of the AR gene were identified. 17 
novel and 5 reported mutations were identified in the affected group, 8 novel and 
5 reported mutations, including one premature stop codon mutation, were 
identified in the related unaffected group and 7 novel and 4 reported mutations 
were found in the controls. Of the above-mentioned mutations, four mutations 
were identified in the activation function-1 (AF-1) domain of exon 1 in 4 
members (3 affected: M-2, F-1 and 1 unaffected: F-1) of the family. All the point 
mutations identified were somatic in nature and were present in heterogeneous 
form i.e wild and mutant (mixture) as determined by cloning. The analysis of 
exons 2 through 8 revealed completely WT sequences. Conclusions: The (CAG)n 
and (GGN)n repeat analysis showed an indeterminate association with MAIS and 
BC in the family. Generation specific patterns of (CAG)n were detected and 
suggest generation specific modulation of the AR. Novel mutations including AF-
1 region mutations were identified in exon 1. The disruption of the AF-1 domain 
may affect the transactivation activity of the AR. 
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CHAPTER 1 
1. INTRODUCTION 
1.1 Significance of the Androgen Receptor 
In 1949 Arnold A. Berthold was the first to state that it was the testes that was 
responsible for the synthesis of a substance which acts through the bloodstream. 
The term 'Testosterone' was coined 86 years later by ‘Ernst Laqueur’ and his co-
workers, and it was shown to be the key factor in controlling the development and 
maintenance of male sexual characteristics (Freeman et al., 2001; Nieschlag, 
2010). 
The action of testosterone occurs via a single intracellular receptor protein defined 
as the ‘Androgen receptor’ (AR). The AR fulfills prominent roles in males as well 
as females. In males the AR is primarily involved in normal virilization of the 
urogenital tract during embryogenesis, masculinization of the male phenotype at 
puberty, and maintenance of the male sex organ function during adulthood 
(Migeon et al., 1984; Cunha, 1994; Sheckter et al., 1989; Yong et al., 2003). 
In females, it helps to maintain the growth and development of the mammary 
gland. The biological roles of the androgen hormone and the involvement of the 
AR accomplish a vital role in normal maintenance of both the sexes (Zegarra-
Moro et al., 2002). 
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1.1.1 Androgen receptor-nuclear receptor/transcription factor 
The AR is grouped under the family, class I of the nuclear steroid receptor, also 
termed as NR3C4 (Nuclear receptor subfamily 3, group C, member 4 (Brinkmann 
et al., 1992; Brown et al., 1989). It is highly expressed in genital and some non-
genital tissues which are typically androgen dependent, such as muscles, prostate, 
seminal vesicles, epididymis and testis. Though present in a lesser quantity the 
AR is also found in several other organs e.g. hypothalamus, pituitary, kidney, 
spleen, heart and salivary glands (Gao et al., 2005; Quigley et al., 1995; Lindzey 
et al., 1994; Keller et al., 1996; Gelmann et al., 2002). 
The AR binds to its ligands, testosterone (T) and 5α-testosterone (DHT), with 
high affinity and through the transcription of various genes regulates a broad 
spectrum of physiological processes such as metabolism, organ development, and 
homeostasis (Bocklandt and Vilain, 2007; Komori et al., 2007). They also exert 
major effects on the reproductive system, viz., the prostate and testes, muscles, 
liver, skin, nervous system and immune system (Gao et al., 2002; Culig et al., 
2000b; Gronemeyer et al., 2004; Das et al., 2000). To regulate efficient 
transcriptional control, co-activators and co-repressors also participate to develop 
a transcriptional network which is further regulated by a series of upstream 
signaling systems (O'Malley and Kumar, 2009; Beck et al., 2009). 
As the AR transcriptional complex influences target gene expression any 
dysregulation in the dynamic intracellular AR complex, or resistance of AR 
binding to its ligand, alters the modulation of AR functions. Mutations in the 
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receptor or an alteration in the circulating level of androgens may disturb normal 
homeostasis causing multiple diseases and inherited traits, consisting of endocrine 
and neurological disorders, steroid associated cancers, hyper androgenic 
disorders, prostatic hyperplasia (BPH), androgen insensitivity syndrome (AIS) 
and polycystic ovarian syndrome (PCOS) (Xu et al., 2009; Han et al., 2009; 
O'Malley et al., 2008; Brinkmann et al., 2001; Araujo et al., 2007; Brooke et al., 
2008). 
1.2 Androgen regulation and production 
Androgens are the primary sex steroid hormones of the males, which are also 
known as ‘C19-steroid hormones’. They are essential for the development of the 
human, as it fulfills vital roles for both sexes (Gupta et al., 1977; Debes and 
Tindall, 2002; Heinlein and Chang, 2002). The secretion and regulation of 
androgens are controlled by the hypothalamus and anterior pituitary (Andrew T 
Kicman, 2010). See figure 1. As the result of secretion of the gonadotropin- 
releasing hormone (GnRH) in the hypothalamus the anterior pituitary synthesizes 
two gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) (Krsmanovic LZ et al., 2009). 
The secretion of gonadotropin is under control of a negative feedback mechanism 
operating between the gonads, pituitary and hypothalamus. In the Leydig cells of 
the testes, LH stimulates steroidogenesis, which results in the production and 
release of testosterone, whilst FSH regulates spermatogenesis (Nieschlag, 1997). 
Testosterone acts on the hypothalamus by reducing the hypothalamic pulse and 
4 
 
inhibits the secretion of LH (Sheckter, 1989), whereas the major feedback control 
and secretion of FSH is from the Sertoli cells through the hormone inhibin 
(O'Connor, 2004). 
 
 
Figure 1: Hypothalamic-pitutary-testicular axis showing the principal 
negative feedback mechanism. The pitutary release of LH and FSH from the 
hypothalamus is mediated by GnRH, and binds to definite membrane receptors on 
Leydig cells and Sertoli cells correspondingly, testicular secretion (Leydig cells 
secrets the testosterone and estradiol and Sertoli cells secrets the hormone 
inhibin), act on the anterior pitutary via negative feedback mechanism where they 
excert control of gonadotropin release. (Adapted with permission from Gardner 
and Shoback, 2011) 
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1.2.1 Physiological role of androgens in males and females 
The development of the male can only take place if androgens are present to act 
on target tissues and complete sexual separation (Hughes and Deeb, 2006). 
Testosterone and 5α-dihydrotestosterone (DHT) are the two most fundamental 
physiological androgens which act as ligands for the AR (Avila et al., 1998). 
These are synthesized by the testes and secreted into the bloodstream for 
circulation (Andrew T Kicman, 2010). See figure 2. 
In the middle of first trimester, at around 7-8 weeks of gestation, the synthesis and 
secretion of testosterone, and its conversion to DHT occurs. The initial production 
of testosterone via the Leydig cells is mediated by placental human chorionic 
gonadotropin (hCG). Sexual separation and development prolong through weeks 
14-16 of gestation (White and Speiser, 2000) and by the 16th week, the placental 
hCG levels decrease and fetal LH secretion begins to direct circulating androgen 
levels (Hughes and Deeb, 2006; Speroff, 2005) which helps to maintain normal 
virilization of the urogenital tract during embryogenesis (Bruchovsky and Wilson, 
1968). 
Testosterone is involved in the survival, proliferation and differentiation of the 
Wolffian duct into seminal vesicles, epididymis and ductus deferens, while the 
development of the male external genitalia, together with the penis and scrotum is 
due to the involvement of DHT. At puberty, androgen helps to initiate 
spermatogenesis and the development of accessory sex organs, including the 
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prostate and it is also responsible for the deepening of voice, phallus enlargement, 
and male pattern hair growth (Hughes and Deeb, 2006; Speroff, 2005; Wiener et 
al., 1997; Migeon et al., 1984). 
In contrast, females produce androgens in their ovaries and adrenal glands and in 
smaller quantities in peripheral tissues. According to earlier studies, a minor role 
for the androgen/AR system was indicated in female physiology (Freeman et al., 
2001; Nieschlag, 2010). 
In 2006, the finding of dysfunction of the ovaries in female knockout mice 
missing the AR proved the vital role of androgen action in female reproduction 
(Shiina et al., 2006). Androgens, such as dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone-sulfate (DHEA) -S, secreted by the adrenal glands are 
converted into androstenedione; and also to testosterone by peripheral tissues and 
are the main androgens in normal postmenopausal women (Noman, 1987; Labrie 
et al., 2003). DHEA, DHEA -S and androstenedione, considered as pro-
hormones; act as precursors for androgen and estrogen synthesis as they are not 
able to bind to and activate the AR. 
During fetal reproductive development Mullerian inhibiting substance (MIS) play 
a significant role. It is secreted in the Sertoli cells of the fetal testes which helps to 
control the degeneration of the Mullerian ducts. In the lack of MIS, the Mullerian 
system develops into the female reproductive organ and the uterus. During the 
postnatal period, adrenal and ovarian androgen helps to develop pubic and 
axillary hairs (Hughes and Deeb, 2006; Speroff, 2005). 
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Figure 2: The chemical structure of dihydrotestosterone (DHT) and 
testosterone (T). The conversion of T to DHT by the enzyme 5α reductase. The 
double bond existing between position 4 and 5 of T is reduced to a single bond in 
DHT.  
 
1.3 Androgen insensitivity syndrome (AIS) 
Androgen action mediated by the AR determines the sexual phenotype of males 
and the promotion of spermatogenesis (Noman, 1987). Mutations in the AR gene 
cause functional defects in the AR protein that prevent normal androgen action, 
leading to impaired virilization and producing a wide range of clinical 
presentations, one of which is androgen insensitivity syndrome (AIS) (Grace et 
al., 1970; Hsiang et al., 1987). Androgen insensitivity syndrome (AIS) is a 
common cause for the virilization disorders.  
Androgen insensitivity is an X- chromosome linked disorder in which individuals 
with a 46, XY karyotype develop secondary female sexual characteristics. In this 
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syndrome, androgens are synthesized but the receptor fails to respond resulting in 
failure of complete male genital development and is mainly due to mutations in 
the AR gene. Typically, there is elevated feminization or under masculinization of 
external genitalia during birth and at puberty growth of abnormal secondary 
sexual characters and infertility (Abdullah et al., 1998). Some mutations in the 
AR are also associated with gynecomastia and male breast cancer. 
AIS includes gynecomastia, testicular atrophy, oligospermia, azoospermia 
(absence of sperm in semen) and elevated serum gonadotropins. Depending on the 
degree of virilization of the external genitalia the AIS phenotype has been 
classified into 7 types, clustering into one of the 3 broad subtypes i.e. Complete 
Androgen Insensitivity Syndrome (CAIS), Partial Androgen Insensitivity 
Syndrome (PAIS) and Mild Androgen Insensitivity Syndrome (MAIS) (Aiman et 
al., 1979). 
1.3.1 Prevalence of Androgen Insensitivity Syndrome  
The prevalence of AIS is estimated to be between "1 in 20,000 to 1 in 90,000 
male births" (Hughes and Deeb, 2006) and CAIS is expected to occur in "1 out of 
every 20,400 46, XY births" (Mazen et al., 2010). PAIS is estimated to occur in 
"1 in 130,000 46, XY births" (Mazen et al., 2010) whereas the prevalence of 
MAIS is unknown (Galani et al., 2008). A literature search found no study 
documenting any difference in prevalence based on ethnicity, geography or 
exposure. 
1.3.2 Complete Androgen Insensitivity Syndrome (CAIS) 
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CAIS was first described in the 19th century. Both Queen Anne and Joan of Arc 
were seemingly affected by CAIS (Hughes and Deeb, 2006; Bakan, 1985). This 
disease is also known as “testicular feminization” syndrome and was first 
described by John Morris in 1953 (Morris, 1953). It is a rare form of male 
pseudo-hermaphroditism characterized by a 46, XY karyotype (Speroff, 2005; 
Robby, 2003). 
In 1989 the exact localization of the human AR gene was discovered, located on 
the Xq11.2-12 chromosome (Brown et al., 1989). The first indication that the AR 
itself is defective in androgen insensitivity came from androgen binding studies 
on genital skin fibroblast cell lines from AIS subjects (Keenan et al., 1974). 
Brown et al., in 1989, published the first evidence that mutations in the AR gene 
cause AIS (Brown et al., 1989). The absence of, or defective, androgen binding 
was observed in the majority of CAIS cases and suggests a severe deficit in 
androgen receptor function (Lubahn et al., 1988b). The final evidence for the 
molecular nature of AIS was reported on the basis of sequencing results of the 
intron - exon boundary of the human AR gene in 1989 (Lubahn et al., 1989). 
1.3.2a Presentation of CAIS 
It was in the early description of CAIS that the mechanism of androgen resistance, 
and not androgen deficiency, was found to be responsible for clinical 
presentation. The nomenclature of testicular feminization has been changed to 
androgen insensitivity syndrome (AIS), and was redefined by discovering the 
normal level of urinary 17-ketosteroid (Morris, 1953). 
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In complete AIS, the activity of AR is completely absent. This results in the birth 
of a phenotypically normal female with a male (46, XY) genotype, and high 
physiological levels of T and DHT can be seen in these patients due to the lack of 
the negative feedback mechanism (Morris, 1953; Lubahn et al., 1989). The 
female infant presents with an inguinal hernia. Recent statistics reveals a 1.1% 
incidence rate of CAIS in children with a premenarcheal inguinal hernia while 80-
90% of girls with CAIS eventually develop an inguinal hernia (Gans and Rubin, 
1962; Sarpel et al., 2005; Viner et al., 1997). However at puberty, the female 
adolescent presents with primary amenorrhea. Scant or absent axillary pubic hair 
is the most common symptom, but breast development is normal. Height is 
generally normal, and examination of sex organs shows normal external genitalia 
with a rudimentary blind end vagina (Viner et al., 1997). 
According to Griffin et al., CAIS individuals have completely female external 
genitalia, a paucity of axillary and pubic hair and the absence of Wolffian duct 
derivatives (Griffin et al 1980; Chaung, 2001). Whereas, according to Quigley et 
al, CAIS has complete female external genitalia without pubic hair, but remnants 
of Wolffian duct derivatives may be found (Quigley et al., 1992). 
1.3.3 Partial Androgen Insensitivity Syndrome (PAIS) 
PAIS is only one etiology of DSD (Disorder of sex development), also known as 
“Reifenstein” syndrome or "Infertile male syndrome" (Quigley et al., 1995). It is 
a heterogeneous form of CAIS presenting with varying degrees of female 
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virilization or male feminization due to differing degrees of AR activity. (Quigley 
et al., 1995; Giwercman et al., 2002).  
In PAIS, the response of cells towards the androgens is incomplete (partial) which 
results in the impairment of the masculinization of male genitalia in the 
developing foetus, and it also affects male adolescent, secondary sexual characters 
during puberty. In females sexual development is normal (Quigley et al., 1995; 
Hughes and Deeb, 2006; Galani et al., 2008; Boas et al., 2006). This explains the 
clinical significance of genetic males with a 46, XY karyotype who show 
insensitivity to androgens (Hughes and Deeb, 2006). 
1.3.3a Presentation of PAIS 
In PAIS individuals, the symptom of feminization is less than that compared with 
CAIS patients. PAIS individuals present with a micropenis, perineal hypospadias, 
and cryptorchidism. Depending on the biochemical nature of the AR, the 
Wolffian duct derivatives are incomplete or completely developed. Hormonal 
analysis reveals increased level of LH, T and estradiol at puberty. Affected 
individuals may develop gynecomastia, small size of the phallus, reduced number 
of sperm or azoospermia in the testes can be seen. Individuals at puberty may 
develop in situ carcinoma (Melo et al., 2003). The PAIS presentation also shows 
the symptom of "Anosmia", in which the sense of smell is lost (Vincent et al., 
1991). Assignment of sex is extremely complicated in these patients, as they show 
ambiguous genitalia during birth. The genitalia may resemble a male; but may 
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include abnormalities such as cryptorchidism, a micropenis and hypospadias. 
Alternatively, the appearance may be essentially feminine (Quigley et al., 1995). 
1.3.4 Mild Androgen Insensitivity Syndrome (MAIS) 
MAIS was described in 1979, by Aiman et al., in 3 unrelated men with long 
histories of infertility and a normal male phenotype with idiopathic oligospermia 
(Aiman et al., 1979). Their group later confirmed it as MAIS based on qualitative 
and quantitative abnormalities in the cytoplasmic androgen receptor (Aiman et al., 
1979; Aiman and Griffin, 1982), and it has also been described that the condition 
for MAIS was the result of male infertility evaluations (Yong et al., 2003; 
Gottlieb et al., 2005).  
1.3.4a Presentation of MAIS 
MAIS currently represents an under explored area. MAIS has been identified in 
small subset of men with male infertility characterized by oligospermia or 
azoospermia, normal serum testosterone levels and elevated LH concentrations. In 
MAIS males genetic studies have demonstrated defects and mutations of the AR 
gene. These men have normal male external genitalia and male gender 
orientation. An unambiguously male phenotype with some degree of 
undervirilization with or without some degree of infertility, is characteristic of 
MAIS. The incidence of MAIS is unknown but may account for a proportion of 
male infertility resulting from azoospermia or oligospermia. These individuals 
may present with mild hypospadias, a normally formed but small phallus, or a 
male phenotype accompanied by sperm deficiency. Some individuals may have 
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gynecomastia resulting from increased testosterone levels and its conversion to 
estrogen. Some subjects are undervirilized and have gynecomastia, but are fertile 
(Grino et al., 1988). Gynecomastia may eventually turn into a cancerous tumour. 
Breast cancer in men, which is extremely rare, constitutes only 0.2% of all 
cancerous tumours in men (Boring et al., 1994; Bembo and Carlson, 2004; 
Derkacz et al., 2011).  
In one subject with MAIS, administration of pharmacologic doses of androgen 
improved virilization, facial and pubic hair development, and lowered voice pitch 
(McPhaul et al., 1991). In another MAIS subject, administered androgen 
successfully corrected the infertility (Yong et al., 1994). All the MAIS subjects 
classically present with high plasma LH levels, despite high plamsa 
concentrations of T (Boyar et al., 1978). Some MAIS subjects have androgen-
binding defects including upregulation of receptor levels, and increased 
dissociation rates of AR (Grino et al., 1988). In phenotypically normal men 
(Ferlin et al., 2007; Pinsky et al., 1989) idiopathic azoospermia or oligosperima 
(Aiman and Griffin 1982) is common. Reduced potency of the AR in MAIS 
subjects has been shown to be caused by mutations in the HBD of the AR.  
These males show increased amounts of serum LH, T and 
estradiol levels and low volumes of seminal fluid during ejaculation, which is a 
clear indication of androgen insensitivity. However symptoms in MAIS 
affected males varies according to mutations in the AR gene (Ferlin et al., 
2007). 
14 
 
In some patients the external genitalia might not be developed properly, which is 
the major reason for the infertility. The coronal hypospadias and the central raphe 
of the scrotum are simple (Concato et al., 1992). At puberty, MAIS can have 2 
phenotypic forms, both presenting with varying degrees of gynecomastia. 
There could be two different phenotypic forms of MAIS, in one form of 
phenotype, infertility and impairment of spermatogenesis can be seen (Migeon et 
al., 1984; Cundy et al., 1986; Mazen et al., 2010) whereas, in the other form of 
MAIS complete spermatogenesis occurs, which maintains fertility (Pinsky et al., 
1984; Gottlieb et al., 1999a).  
Physical examination of both phenotypic forms reveal high-pitched voices, sparse 
pubic hairs, varying degrees and development of gynecomastia in adolescent 
males. Infants show extremely less hypospadias (Hughes and Deeb, 2006). 
1.4 Androgen receptor gene variation and AIS  
The AR is one of the most mutated of the steroid receptors. According to the AR 
database (http://androgendb.mcgill.ca), of the three functional domains the LBD 
is highly mutated with most of the mutations being missense mutations, and about 
20% of the mutations are located on the DBD (Gottlieb et al., 1999b; Gottlieb et 
al., 2004) and the remaining mutations are located on NTD. AIS is the leading 
genetic cause of male pseudohermaphroditism. An understanding of AIS genetic 
transmission and the related outcome are necessary for clinical decision making, 
especially, because since it has a significant impact on gender identity and the 
patient’s future sex life (Sultan et al., 2002).  
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1.4.1 Somatic mosaicism 
Somatic mosaicism occurs when somatic cells of the body are comprised of 
more than one genotype. In other words, mosaicism refers to the presence of 
genetically distinct cell populations within an organism (Youssoufian and 
Pyeritz, 2002). Boveri et al., in 1929 first formulated the concept of somatic 
mutation and associated these as the cause of cancer. Nonetheless, such changes 
were also linked to ageing and death (Szilard, 1959). One of the main 
characteristics of mosaicism is that when cells undergo changes during 
development one group of cells may differ from a neighboring group due to  
spontaneous DNA mutations, spontaneous reversion of an existing DNA 
mutation, epigenetic changes and chromosomal abnormalities. The phenotypes 
associated with mosaicism depend on the extent of mosaic cell gene population. 
Equally interesting is the observation that even in absence of clear phenotypic 
effects, individuals may accumulate somatic variations. Mosaicism has 
important consequences with respect to human disease and it also results in 
variations among all humans at molecular level, even among identical twins.  If 
the event leading to mosaicism occurs during development, it is possible that 
both somatic and germ line cells will become mosaic. In this case, both somatic 
and germ line tissue populations would be affected, and an individual could 
transmit the mosaic genotype to his or her offspring. Conversely if the 
triggering event occurs later in life, it could affect either a germ line or somatic 
cell population. If the mosaicism occurs only in the somatic cell population, the 
phenotypic effect will depend on the extent of the mosaic cell population; 
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however there would be no risk of passing on the mosaic genotype to offspring. 
On the other hand if the mosaicism occurs only in germ line cell population, the 
individual would be unaffected, but his or her offspring could be affected. 
Somatic mutations in the androgen target tissue have been proposed to 
contribute to phenotypic variation, however data is lacking regarding somatic 
mutations and only few cases i.e. 25 cases of phenotypic variations have been 
reported to date (Gottlieb et al., 2001a; Gottlieb et al., 2001b). 
There are a few studies which have highlighted the role of somatic mutations in 
the androgen receptor (Holterhus et al., 1997; Segawa et al., 2002 and Rajender 
et al., 2007a). Holterhus et al., have reported an exceptional case in an 
individual presenting with PAIS, in whom the outcome of the SHBG-test and 
the phenotype did not match, due to somatic mosaicism (Holterhus et al., 1997). 
There is a global database, the androgen receptor database: 
(http://androgendb.mcgill.ca), which tracks known mutations and their associated 
phenotypes. The total number of mutations has risen from 605 since 2004 to 1029 
in 2012 (Gottlieb et al., 2012). There are approximately 800 known AIS-specific 
AR mutations causing CAIS, PAIS and MAIS (Gottlieb et al., 2012). In the AR 
gene, 4 different types of mutations have been detected in DNA from individuals 
with AIS and include:  
(a) Amino acid substitution or premature stop codons ensuing from a single point 
mutation.  
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(b) Nucleotide insertions or deletions, typically leading to either termination of 
the premature codon or a frame shift mutation. 
(c) Complete or partial gene deletions (>10 nucleotides) and  
(d) Splicing of the AR RNA due to mutations in the splice donor site or the 
acceptor site (Gottlieb et al., 1999a). 
 
 
1.5 Breast Cancer 
Although the focus of much research into the normal and irregular functioning of 
the AR has been conducted in the context of male physiology, the AR also plays a 
pivotal role in female physiology. The normal development and maintenance of 
breast tissue is under the control of the balanced presence of androgens and their 
receptors. When androgen levels rise above normal levels, pre and post-
menopausal females are at a greater risk for the development of breast carcinoma 
(Kaaks et al., 2005a; Kaaks et al., 2005b; Tiefenbacher and Daxenbichler, 2008). 
In 1836, Cooper et al., already suggested an association between ovarian 
secretions and the development of human breast cancer. The expression of the AR 
has been shown in 70% to 90% of primary breast tumors (Kuenen-Boumeester et 
al., 1996; Buchanan et al., 2005). 
Breast cancer is the most common malignancy, and the second leading cause of 
cancer deaths in women throughout the world (Umar et al., 2012; Benson and 
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Jatoi, 2012). By far, the most significant risk factors for breast cancer are gender, 
age, race/ethnicity, and family history (Thomson, 2012).  
The disease is rare before the age of 20, but the rate of growth of the disease 
associated with aging is higher, as compared to the different forms of the cancer 
(Stegeman and Bossuyt, 2012). Several studies have demonstrated an excess of 
familial clustering of breast cancer, suggesting an inherited genetic predisposition 
to the disease (Manjili et al., 2012). As androgens control gene expression, it is 
essential for the mammary gland to maintain the AR function to avoid the 
unwanted effects of androgens (Secreto and Zumoff, 2012). 
The involvement of estrogen and the progesterone mediated activities in both the 
normal growth of breast and in the cancerous breast has been documented (Zava 
and McGuire, 1977). Importantly, the androgen hormone is the predominant sex 
steroid hormone in post menopausal women, a stage of life during which many 
cases of breast cancer are diagnosed. The expression of AR has been found in 
normal breast epithelial cells in approximately 70-90% of invasive breast 
carcinomas (Hu et al., 2011). 
1.5.1 Prevalence of Breast Cancer  
The most recent breast cancer statistics were reported by the National Cancer 
Institute (NCI), USA in 2012. Newly diagnosed breast cancer cases reached 
226,870 with expected related deaths of 39,510. This represents 621 new breast 
cancer cases in females and 108 deaths due to breast cancer occurring everyday 
worldwide per 100,000 of women population. 
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The highest incidence rate is in western countries. American and British women 
accommodate the increased rates of (~92%) breast cancer, along with the rest of 
North Americans, Australians, Eastern and North Europe, and New Zealand 
women (Perkin et al 2005). The lowest incidence rate of (~22%) breast cancer is 
observed among the Japanese, Chinese and possibly other Asian populations 
(Parkin, 2007).  
Demographically, the difference in the incidence rate of the disease between these 
native Asians and African-Asians is approximately 50-fold (Benson and Jatoi, 
2012). Recent statistics indicate that every 1 out of 29 women in South Africa are 
diagnosed with breast cancer (Wadler et al., 2011). See figure 3. 
 
Figure 3: Geographical Prevalence and statistics of breast cancer worldwide in 
2012. The world map highlights the percentage of breast cancer with different 
colors: occurring everyday worldwide per 100,000 of women population. The 
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highest rate is 92%, in pink, 74% in light brown, 57% in yellow, 40% in light 
green and lowest rate is 22%, in light blue. Source: (http://www.faqs.org/sec-
filings/120716/Immunovative-Inc_10-K). 
 
1.6 Androgen receptor gene variation and breast cancer 
Since 1970 it has been known that many cases of human breast cancer have 
defective androgen receptors (AR). The first evidence of the involvement of the 
AR gene in breast cancer came from the observation of a mutation (R607Q) in 
two brothers with breast cancer and partial androgen insensitivity syndrome 
(Wooster et al., 1992). This was followed by another report of a mutation 
(R608L) in another case of male breast cancer (Lobaccaro et al., 1993). 
Several case control studies, in different populations revealed that longer CAG 
repeats in the exon-1 region increase breast cancer risk (Giguere et al., 2001; 
Kadouri et al., 2001; Liede et al., 2003). In contrast many other studies have 
limited the impact of AR CAG repeats on breast cancer (Dunning et al., 1999; 
Haiman et al., 2002; Spurdle et al., 2005).  
The length of this polymorphic tract varies among different population groups. 
Ethnic differences were proposed as a factor affecting the possible variation of 
CAG repeats length (Gonzalez-Perez et al., 2006). It has been shown that Asian 
population has the longest CAG repeats, whereas the African population has the 
shortest, and Caucasians falling in the middle (Nicolas Diaz-Chico et al., 2007; 
Sasaki et al., 2003). 
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Studies conducted in Quebec by Giguere et al., suggest, that the mean CAG 
repeat alleles are 21 (Giguere et al., 2001). However, studies from other 
population groups show differing results. CAG repeats varied from 14 to 31 in 
Japanese patients (Sasaki et al., 2003); 19 to 27 in Filipinos (Liede et al., 2003); 
and 14 to 30 were seen in the Spanish Tenerife population (Gonzalez et al., 2007). 
Several studies, examining CAG repeat polymorphisms in relation to breast 
cancer risk conducted in Caucasian populations have been inconclusive (Gonzalez 
et al., 2007; Elhaji et al., 2001; Rebbeck et al., 1999; Anghel et al., 2006). Some, 
but not all the studies, including those limited to BRCA1 or BRCA1/2 mutation 
carriers, have found an increased risk of breast cancer associated with longer 
CAG repeats, particularly at the younger age (Spurdle et al., 2005; Slattery et al., 
2007; Rebbeck et al., 1999; Jakubowska et al., 2010).  
It is well recognized that cancer is the result of several aberrations in the same or 
different pathways. Therefore, some studies have analyzed the CAG repeats 
length in individuals who were predisposed to cancer due to some other 
aberration; for example, BRCA mutation(s).  
Out of the five studies (Rajender et al., 2007) which analyzed CAG repeat length 
variation in individuals who were BRCA mutation carriers only one study 
(Rebbeck et al., 1999) reported an association of longer CAG repeats with disease 
risk. Whereas, the other four (Kadouri et al., 2001; Spurdle et al., 2005; Dagan et 
al., 2002) reported no association. In these studies, a positive family history of 
breast cancer appeared to be more significant. Only two studies (Haiman et al., 
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2002; Wang et al., 2005b), analyzed the CAG repeats length in individuals with a 
positive family history of breast cancer, and both reported a direct association of 
longer CAG repeats with disease risk.  
Interestingly in other studies, no significant association has been made between 
the AR-CAG repeat length and breast cancer risk in high risk breast cancer 
families (Kadouri et al., 2001; Menin et al., 2001; Lillie et al., 2003).  
A few in vitro studies have detected an association of the longer polymorphic 
allele with reduced AR transcriptional activity, which could further be attributed 
to the lower affinity of androgens to AR and lower androgenic effects (Kazemi-
Esfarjani et al., 1995; Nicolas Diaz-Chico et al., 2007). Similar findings were 
outlined for male breast cancer. Some researchers highlighted a significant 
increase in breast cancer risk only in individuals with a first degree family history 
(FH) of breast cancer who bore alleles longer than 22 (Haiman et al., 2002; Wang 
et al., 2005b). 
In addition, androgens might serve as a modifying factor in breast cancer risk 
among women who are prone to breast cancer (Haiman et al., 2002). AR is also 
known to interact with many tumor suppressor genes (Heinlein and Chang, 2004). 
There are prospective epidemiologic reports that higher circulating androgen 
levels in women are associated with a higher carcinogenic risk of developing 
breast cancer. 
In a review of eight prospective cohort studies, an association of endogenous 
testosterone levels with breast cancer risk was observed (Lillie et al., 2003). 
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Moinfar et al, studied AR expression in formalin-fixed, paraffin embedded 
archival specimens in 200 cases of breast cancer (Moinfar et al., 2003); 60% of 
145 cases of invasive carcinoma and 82% of 55 cases of ductal carcinoma, in situ 
were AR positive. The great majority of well differentiated carcinomas were both 
AR and ER positive. Notably, in poorly differentiated carcinomas, 39% were ER 
negative, but AR positive. Also, in inadequately differentiated carcinomas, 30.5% 
were both AR and HER2/neu positive, while 42.5% were both AR and HER2/neu 
negative. 
Furthermore, carcinomas with apocrine differentiation were usually AR positive 
and ER negative, while most invasive lobular carcinomas were AR positive and 
ER positive. Doane et al., point out the heterogeneity of AR expression in breast 
cancer, as well as, the complexity of AR signaling in breast cancer (Doane et al., 
2006). 
Agoff et al., studied AR expression in a series of ER negative breast cancers. This 
subset is of particular interest because ER negative cancers would not be expected 
to respond to ER blockade or aromatization inhibition (Agoff et al., 2003). ER 
negative cancers which are AR positive might shed light on the biological 
significance of AR expression. Overall, AR expression correlated with 
significantly longer survival rates, in a cohort of women with ER negative tumors. 
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1.7 REVIEW OF ANDROGEN RECEPTOR LITERATURE 
1.7.1 Structure of the androgen receptor gene 
Along with other nuclear receptors such as, Progesterone receptor (PR), 
Glucocorticoid steroid receptor (GR), Mineralocorticoid receptor (MR), Vitamin 
D receptor (VDR) and Estrogen Receptor (ER), the Androgen Receptor (AR) also 
falls under the "NR3C4" super family (Brinkmann et al., 1992; Brown et al., 
1989). 
The human AR gene is localized to the proximal, long arm of the X-chromosome 
at position Xq11.2-12 (Lubahn et al., 1988b; Kuiper et al., 1989). It occupies over 
90 Kb of DNA, consisting of 920 amino acids according to the updated version of 
AR database (http://androgendb.mcgill.ca) (Gottlieb et al., 2012), with a 
molecular mass of 110 kDa (Lubahn et al., 1988a). 
The AR gene is encoded by 8 exons and has two untranslated regions: a large 
untranslated region towards the 5’ end (5’-UTR, 1.1kb in size) and a very large 
3’-untranslated region (3’-UTR, 6.8-kb in size) (Faber et al., 1991; Kuiper et al., 
1989). Figure 4 illustrates the AR gene organization and domain structure of the 
protein. The AR has four functional domains: 
 (i) a NH2-transactivation domain (NTD) (Amino acids 1 to 538),  
(ii) a DNA binding domain (DBD) (Amino acids 539 to 628), 
(iii) a Hinge region and 
(iv) a COOH-terminal ligand binding domain (LBD) (Amino acids 629 to 920). 
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Figure 4: Structure of the AR gene: Location of the AR gene on the 
chromosome - X is shown in A. The intronic and exonic arrangement of the 
genome, spanning more than 90Kb is shown in B. The location of three 
trinucleotide repeat regions, in the exon 1, which codes for transactivation 
domain, is shown in C. The representation of the protein structure demonstrates 
how the exon organization translates into the distinct functional regions of the 
receptor. Reprinted with permission from, American Society of Clinical 
Oncology, 2002. (Adapted from Edward P. Gelmann, 2002). 
 
The NCBI accession number for the nucleotide and amino acid sequence of the 
human AR is as referred to in a recent updated version of the androgen receptor 
database (http://androgendb.mcgill.ca) NM_000044.2 (Gottlieb et al., 2012). 
Figure 5 illustrates the amino acid sequences of each domain.
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 1                                                                                                         100 
 MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ QQQQQQQQQQ QQQQQQQQQQ ETSPRQQQQQ QGEDGSPQAH 
 
 101                                                                                                       200 
 RRGPTGYLVL DEEQQPSQPQ SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSAA PSTLSLLGPT FPGLSSCSAD LKDILSEAST MQLLQQQQQE 
 
 201                                                                                                       300 
 AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG 
 
 301                                                                                                       400 
 KSTEDTAEYS PFKGGYTKGL EGESLGCSGS AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ SRDYYNFPLA LAGPPPPPPP PHPHARIKLE NPLDYGSAWA 
 
 401                                                                                                       500 
 AAAAQCRYGD LASLHGAGAA GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP YGYTRPPQGL AGQESDFTAP 
 
  501                                                                                                       600 
 DVWYPGGMVS RVPYPSPTCV KSEMGPWMDS YSGPYGDMRL ETARDHVLPI DYYFPPQKTC LICGDEASGC HYGALTCGSC KVFFKRAAEG KQKYLCASRN 
 
 601                                                                                                       700 
 DCTIDKFRRK NCPSCRLRKC YEAGMTLGAR KLKKLGNLKL QEEGEASSTT SPTEETTQKL TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA 
 
 701                                                                                                       800 
 LLSSLNELGE RQLVHVVKWA KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFTNVNS RMLYFAPDLV FNEYRMHKSR MYSQCVRMRH LSQEFGWLQI 
 
 801                                                                                                       900 
 TPQEFLCMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD RIIACKRKNP TSCSRRFYQL TKLLDSVQPI ARELHQFTFD LLIKSHMVSV DFPEMMAEII 
 
 901               920 
 SVQVPKILSG KVKPIYFHTQ  
 
 
Figure 5: The amino acid sequence of human androgen receptor gene, NCBI accession number NM_000044.2. The diagram 
highlights the domains by different colors; NH2-Transactivation domain (Blue), DNA binding domain (Red) and Ligand binding 
domain (Green). 
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1.7.2 Androgen Receptor Domains 
1.7.2.1 Transactivation Domain 
The transactivation domain is the largest domain, representing nearly half of the 
receptor coding sequence (Quigley et al., 1995) consisting of amino acids 1 to 
538, encoded by exon 1. The NTD is involved in significant transactivation 
function and also assists in homeostatic control and AR signaling complexity (Li 
and Al-Azzawi, 2009). 
Within the NTD, Activation function-one (AF-1) has been identified (aa 142-
485), which is modular in nature. It serves as an important transactivation 
function, due to the presence of hydrophobic amino acids (Simental et al., 1991; 
Jenster et al., 1995). A few residues (224-258) in the AF-1 domain are highly 
conserved in exon 1 of the AR, from fish through to primates, and these highly 
conserved hydrophobic amino acids have been shown to be essential for AR 
activity and protein-protein interaction (Betney and McEwan, 2003). 
AF-1 is composed of sequences which are constitutively active in the absence of a 
ligand. It is generally responsible for the recruitment of co-activator/co-repressor 
molecules, to create active pre-initiation complexes; through a TATA box and 
pol- II, for the regulation of the target gene transcription (Lamont and Tindall, 
2010). The NTD of AR AF-1 is known to robustly interact with the LBD, which 
may further stabilize the AR bound androgen network, and play a role in receptor 
dimerization (He and Wilson, 2002; Farla et al., 2004).  
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AF-1 consists of two sub-regions, named AF1-a and AF1-b corresponding to 
residues '154 SSC to SEA 167' and '295 SAG to DYY 359' respectively 
(Chamberlain et al., 1996). AF1-a is predicted to contain a β-turn followed by an 
acidic amphipathic α-helix. AF1-b is defined by a glutamate (E) and aspartate (D) 
residue organization, which is similar to an acidic activation domain (Triezenberg, 
1995; Chamberlain et al., 1996). The definite function of these two sub-regions,  
in mediating androgen regulated transcription of genes has not been determined 
(Ikonen et al., 1997).  
Two transcription activation units (TAUs) have been recognized in the N-terminal 
domain; TAU1 at amino acid residues 100-370 and TAU5 at the amino acid 
residues 360-528. They are accountable for receptor dependent trans-activation 
(Jenster et al., 1995; Callewaert et al., 2006). 
The first 20 amino acids of the NTD contains a "FxxLF" motif (where x is any 
amino acid) which is beneficial for interacting with the LBD and results in an 
amino/carboxyl terminal interaction (N/C interaction). It has been implicated that 
this kind of interaction could be crucial for the transcriptional activation of some 
AR target genes (He and Wilson, 2002; Steketee K et al., 2002). 
Inside the exon 1 transactivation domain, three microsatellite regions are 
described; each made up of the amino acid repeats glutamine (Q), glycine (G) and 
proline (P) which characterize the AR from other receptors of the NR3C4 super 
family (Mooradian et al., 1987; Janne and Shan, 1991; Janne et al., 1993). Of the 
three microsatellite regions, two are highly polymorphic in length; these are the 
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upstream glutamine, a classic repeat (referred to as the Poly-Q region) and the 
downstream glycine complex repeat (referred to as the Poly-G region) (Hughes 
and Deeb, 2006). The reason for the high polymorphic nature is due to the 
‘slippage’ of DNA polymerase on the multiple glutamine in the template DNA, 
which results in inconsistencies "in the final set of glutamine repeats copied 
during DNA replication" (Gelmann, 2002). While the proline repeats are a non-
polymorphic stretch of 8 residues from 374-381, the glutamine repeats begin at 
amino acid residue 58 and the glycine repeats begin at residue 451 (See figure 6). 
The glutamine repeat sequence, ranges from approximately 10 to 30 repeats, with 
an average length of 22 repeats (Lundin et al., 2006). Ethnic differences in the 
glutamine repeat range are well known (Kittles et al., 2001) as discussed 
previously in section 1.6. 
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 1                                                                                                         100 
 MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ QQQQQQQQQQ QQQQQQQQQQ ETSPRQQQQQ QGEDGSPQAH 
 
 101                                                                                                       200 
 RRGPTGYLVL DEEQQPSQPQ SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSAA PSTLSLLGPT FPGLSSCSAD LKDILSEAST MQLLQQQQQE 
 
 201                                                                                                       300 
 AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG 
 
 301                                                                                                       400 
 KSTEDTAEYS PFKGGYTKGL EGESLGCSGS AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ SRDYYNFPLA LAGPPPPPPP PHPHARIKLE NPLDYGSAWA 
 
 401                                                                                                       500 
 AAAAQCRYGD LASLHGAGAA GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP YGYTRPPQGL AGQESDFTAP 
 
  501                                   538                                                                  
   DVWYPGGMVS RVPYPSPTCV KSEMGPWMDS YSGPYGDM 
 
 
Figure 6: Androgen receptor NH2-transactivating domain amino acid residue 1 to 538, NCBI accession number NM_000044.2. The 
activating function-1 (AF-1) region (residues 144 to 486) are underlined; AF1-a sub region is shown in blue and AF2-b is shown in 
green; poly Q, poly P and poly G repeat sequences are shown in pink. The most conserved region is shown in bold italic purple.
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1.7.2.2 DNA Binding Domain 
The DNA binding domain encoded by exon 2 and 3 is highly conserved. It is rich 
in amino acid cysteine, which is involved in the creation of 2 zinc clusters; 
arranged as a pair of loop structures folded to create a single structural unit, made 
up of two zinc binding motifs (Gelmann, 2002; McEwan, 2004; Verrijdt et al., 
2003; Hughes and Deeb, 2006; Alvarez-Nava et al., 1997; Simental et al., 1991; 
Wong et al., 1993; Freedman, 1992) followed by a C-terminal extension. 
The first zinc finger contains the so-called proximal (P)-Box, which interacts with 
the DNA major groove of the Androgen Response Elements (ARE) and 
determines the specificity of DNA recognition. The different types and 
categorization of androgen response elements are given in the table 1, (Claessens, 
2001). The second zinc finger contains a distal (D)-box, consisting of 5 amino 
acids (ASRND) and is involved in AR homo-dimerization and DNA/receptor 
complex stabilization (Gelmann, 2002). 
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Table 1: Different types and classification of androgen response elements. 
Reprinted with permission from, the Journal of Steroid Biochemistry and 
Molecular Biology, 2001. (Adapted from Claessens 2001). 
 
 
In general, these zinc fingers are responsible for specific binding of transcription 
factors to cognate DNA elements that are organized as inverted repeats of 
hexameric binding sites (5’-TGTTCT-3’NNN5’-TGTTCT-3’), separated by three 
nucleotide spacers (See figure 7). Nucleotide sequence-specific DNA binding of 
receptors to their respective response elements leads to DNA binding suggesting 
that interactions between different cis-acting factors bound to DNA can occur, by 
drawing them into proximity within the transcriptional activation system. In 
addition, the DNA binding of AR may be influenced by its interaction with other 
nuclear proteins (Gelmann, 2002; McEwan, 2004; Verrijdt et al., 2003; Hughes 
and Deeb, 2006; Alvarez-Nava et al., 1997). 
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539.......RLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLG.......628 
 
 
 
 
Figure 7: Amino acid sequence (539 to 628) of the AR DNA binding domain. NCBI accession number NM_000044.2. Zinc finger 
sub domains are shown in blue; Cysteine residue coordinating with zinc atoms are in large bold, P and D boxes are highlighted in the 
rectangle boxes. 
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1.7.2.3 Hinge region 
A hinge region is located between the 3' end of exon 3 and 5' region of exon 4, 
consisting of flexible amino acid sequences (Janne and Shan, 1991). It contains 
the main nuclear localization signal (NLS) of the receptor, which is encoded by 
the 5’ portion of the exon 4, and spans approximately 51 amino acids (625-676) 
(MacLean et al., 1997; Jenster et al., 1991).  
The NLS consists of two essential amino acid clusters found in the DBD and 
hinge, from amino acid 617-633 (RKCYEAGMTLGARKLKK) (Zhou et al., 
1994). The binding of androgen to the AR causes a receptor conformational 
change that regulates the NLS activity and translocation of the androgen in the 
AR complex into the cell nucleus (MacLean et al., 1997; Zilliacus et al., 1992).  
The 280 kDa of cytoskeletal protein Filamin-A (FlnA) is derived from an actin 
binding domain (ABD), and 24 sequential stick like domain repeats also involve 
in nuclear translocation (Ozanne et al., 2000; Wang et al., 2005). The interaction 
of the cytoskeletal protein FlnA with the DBD, LBD and hinge, promotes the 
nuclear translocation of AR.  
The hinge region is also required for intra-protein interaction between AF-1 and 
AF-2 domains. Deletion of NLS in the hinge region causes a partial reduction of 
AR's translocation into the cell nucleus, suggesting that a second NLS is also 
involved in translocation, which is available in the LBD (Zhou et al., 1994). 
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1.7.2.4 Ligand Binding Domain 
The carboxyl terminal region of the AR contains the ligand binding domain (aa 
677-920) encoded by 3’ region of exon 4 and exons 5-8 
(http://androgendb.mcgill.ca/). The structure of the androgen receptor-LBD (AR- 
LBD) is similar to the LBD of other steroid hormones such as PR, GR, ER, MR 
and others (Matias et al., 2000; Sack et al., 2001). 
The high affinity interaction between the AR and its steroidal and non-steroidal 
ligands occurs through LBD, and is also involved in the recruitment of co-
regulators during transcriptional activation (Heemers and Tindall, 2007). The 
LBD is also involved in the interaction of AR with chaperons. Please refer to 
figure 8. 
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601                                                                                                       700 
DCTIDKFRRK NCPSCRLRKC YEAGMTLGAR KLKKLGNLKL QEEGEASSTT SPTEETTQKL TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA 
 
701                                                                                                       800 
LLSSLNELGE RQLVHVVKWA KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFTNVNS RMLYFAPDLV FNEYRMHKSR MYSQCVRMRH LSQEFGWLQI 
 
801                                                                                                       900 
TPQEFLCMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD RIIACKRKNP TSCSRRFYQL TKLLDSVQPI ARELHQFTFD LLIKSHMVSV DFPEMMAEII 
       
      901               920 
      SVQVPKILSG KVKPIYFHTQ 
 
 
 
Figure 8: Amino acid residues 629 to 920 of the human androgen receptor (AR), Hinge region and Ligand binding domain. NCBI 
accession number NM_000044.2. The residues involved in electrostatic interaction with co-regulators are highlighted in the 
rectangular box.
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1.7.2.4a 3D- Structure of the LBD 
The 3D-crystallographic structure of the LBD was described early in the previous 
decade (Sack et al., 2001). Similar to other steroid hormone receptors the 3D-
structure of AR- LBD established 12α helices and 4 short β–strands arranged in 2- 
β sheets, folded into a three-layer sandwich-like structure (Wadler et al., 2011; 
Matias et al., 2000; John et al., 2000) Figure 9 a. 
 
 
Figure 9a: The 3D-crystallographic structure of AR LBD. Reprinted with 
permission from Proceedings of the National Academy of Sciences, 2001, USA. 
(Adapted from John.S.Sack et al., 2001). 
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The 3D-crystallographic structure revealed the ligand binding pocket allowing 
interaction with surface binding proteins, and with co-activators and co-
repressors. The ligand binding pocket of the AR-LBD consists of about 20 amino 
acid residues which communicate with the bound ligand (Matias et al., 2000) and 
is flexible in nature capable of recruiting ligands with different structures.  
Following hormone binding helix12 folds back into the core of the LBD allowing 
closure of the ligand binding pocket (Giammanco et al., 2005; Singh et al., 2006; 
Lubahn et al., 1988b; Brinkmann et al., 1989). Thus, conformational change 
occurs in the LBD resulting in the stabilization of helix 12 and the creation of 
functional AF2 on the surface. The structural organization of AR-LBD is shown 
in the figure 9b. 
The role of AF2 in the LBD is mainly dependent on availability of nuclear 
receptor co-activators. A ligand dependent functional interaction of AF2 region in 
the LBD with the NTD is supported by in vivo experiments (Langley E et al., 
1995; Berrevoets CA et al., 1998). 
Deletions in the LBD entirely disrupt hormone binding (Jenster G et al., 1991), 
while the deletions in the NTD and DBD do not affect the hormone binding. Five 
codons within exons 6 and 7 of the human AR encoding the LBD act as “hot 
spots” for mutations based upon their relative frequency of mutation and the 
alternative amino acid substitutions that occur within each codon (Murono et al., 
1995). 
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Figure 9b: Structural organization of androgen receptor. Top: Schematic 1D 
amino acid sequence of androgen receptor. Bottom: 3D structures of DBD bound 
to DNA and LBD bound to hormone regions of androgen receptor. This figure is 
adopted from the website (http://en.wikipedia.org/wiki/Nuclear_receptor). 
 
1.8 Mechanism of AR action 
An outline of how AR mediates the biological effects of androgens is known 
(Mooradian et al., 1987; Lamont and Tindall, 2010; Janne and Shan, 1991; Janne 
et al., 1993). The regulation of cellular proliferation and differentiation of 
androgens occurs through the AR. A schematic diagram showing the mechanism 
of action of the AR is shown in figure 10. This process requires at least 30-40 
minutes altering the expression of genes, whereas it requires hours to create 
significant levels of newly expressed proteins. 
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Testosterone enters the target cell via the plasma membrane and is converted into 
DHT by the help of enzyme 5-α-reductase type II, and interacts with the AR 
present in the cytoplasm. When the ligand is not present, the AR is maintained in 
an inactive form by molecular chaperon heat shock proteins (HSP) 90, 70, 56 and 
p23-a. A co-chaperon stabilizes the binding of HSP- 90 to the receptor together 
with various co-chaperons including cyclophilin 40 (Cyp40), and FK506-binding 
protein 52(FKbp52), to prevent the constitutive activation of the receptor and is 
dispersed throughout the cytoplasm (Culig et al., 2000a).  
When the ligand binds the C-terminal helix-12 in the LBD shifts position to block 
the ligand binding pocket. This results in the separation of heat-shock proteins 
that results in facilitating the AR to network with co-regulators, such as ARA-70 
(binds to AR-DBD and AR-LBD), cytoskeleton protein filamin-A and importin-α, 
which binds to the AR nuclear localization signal (NLS). 
This network encourages the nuclear targeting of AR and the formation of homo-
dimers. It also facilitates a series of conformational changes in the AR-LBD with 
the help of helices 3 and 5 and the subsequent release of co-repressor complexes 
(Bennett et al., 2010). The AR-DHT complex then travels to the nucleus where it 
binds to specific chromosomal DNA sequences (ARE) in the regulatory regions 
(promoter/enhancers) of the AR-regulated gene. Subsequently, the recruitment of 
co-regulators and general transcription factors take place through the activated 
AR, which leads to the development or control of the target genes (Culig et al., 
2000a; Bennett et al., 2010). The nature of AR-bound ligands determines the 
strength of AR-DNA complexes and eventually transcription is initiated. Under 
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normal physiological conditions, only half of the total cellular AR molecules are 
thought to be occupied by the ligand for mediating androgen action. The 
remaining half of unliganded AR is proposed to regulate other cellular events 
such as the cell cycle (Ma et al., 2001; Yamamoto et al., 2000). 
Recent chromatin immunoprecipitation (ChIP) studies suggest that the ER and 
AR agonists recruit co-regulators cyclically in a time-dependent manner to 
suitable response elements (Shang et al., 2002; Wang et al., 2005a). Once  
transcription is initiated, the AR separates from the DNA and moves to the 
cytoplasm where it undergoes ubiquitination and proteolytic cleavage. In the next 
round, the transcriptional activation take place with a fresh receptor and the cycle 
continues in the presence of a fresh ligand (Cardozo et al., 1998; Pajonk et al., 
2005). The unbound AR either shuttles back to the cytoplasm for a recycling 
process or gets degraded by the proteosomal degradation process. 
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Figure 10: AR cycle. The androgen receptor (AR) (coloured orange) is illustrated 
as a modular protein with each of its domains represented; NTD (N-terminal 
transactivation domain), DBD (DNA-binding domain), the hinge and the LBD 
(ligand-binding domain).  (1) Conversion of testosterone to DHT via the enzyme 
5-reductase in basal epithelial cells within the prostate; (2) DHT moves into the 
cytoplasm of epithelial cells where it is bound by AR; (3) Ligand binding to AR 
induces an AR conformational change, whereby proteins such as heat shock 
proteins (HSPs) dissociate and others such as importin- and the androgen 
receptor-associatedprotein-70 (ARA70) are recruited to help stabilise AR and (4) 
promote AR nuclear translocation; (5) AR dimerises in the nucleus; (6) Numerous 
other co-activators bind to the AR in the nucleus, then the AR-DBD facilitates 
nucleic acid binding at androgen response elements (ARE) which promote the 
recruitment of co-activators with histone acetyltransferase (HAT) activity 
(CBP/p300, P/CAF), via SRC/p160 co-activator family members, resulting in 
chromatin remodelling. This allows the binding of the TATA binding protein 
(TBP), followed by general transcription factors (GTF) and RNApolII to begin 
transcription; (7) Non-ligand-bound AR is shuttled back to the cytoplasm and 
recycled in preparation for further ligand binding. (8) Alternatively, non-ligand-
bound AR can be targeted for proteosomal degradation following ubiquitination 
by E3 ubiquitin ligase. Reprinted with permission from, the International Journal 
of Biochemistry and Cell Biology, 2010. (Adapted from Bennett et al., 2009). 
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1.9 AIMS 
 The overall aim of this work is to examine the relationship between AR-CAG 
repeat length polymorphisms, AR-GGN repeat length polymorphisms of exon 1 
of AR gene and point mutations of the AR gene in affected males with MAIS and 
gynecomastia and breast cancer affected females of the enrolled family. The 
specific aims are: 
 To examine whether the CAG repeat length of exon 1, have any impact on 
the MAIS and breast cancer subjects participating in this familial study. 
 To examine whether the GGN repeat length of NTD, have any impact on 
the MAIS and breast cancer subjects of the present study. 
 To investigate, if any point mutations of the androgen receptor gene are 
linked to the MAIS/gynecomastia and breast cancer in the individuals in 
the enrolled family . 
 To identify the somatic mosacism in exon I region using cloning. 
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CHAPTER 2 
2. MATERIAL AND METHODS 
2.1 Ethical considerations 
This study was approved by the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand. The ethics clearance number is M121194, 
Appendix A. 
2.2 A Family Pedigree included in the study, its three components and 
analysis 
A South African family of Indian descent was enrolled in this study. In this family 
several males were affected with MAIS and gynecomastia, and the females were 
affected with an aggressive early onset of breast cancer. A pedigree chart was 
drawn up and is shown in the figure 11. 
In this family pedigree, there were a total of 34 members, of which only 16 were 
involved in the present study and the other 12 members refused to participate. Six 
members of the family were deceased of which the 2 females died as a result of 
breast cancer and two males with MAIS and gynecomastia. The other deceased 
male and female died of natural causes. 
The index case was a married phenotypic male of second generation (G2) who 
was unaffected but the father of the index case (G1) was suspected to be affected 
with MAIS and gynecomastia. A detailed family history was obtained by all the 
members of the family who were willing to participate in the study. All patients 
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were being treated by Prof. Girish Modi, Neuroscience department, Charlotte 
Maxeke hospital, University of Witwatersrand and clinically diagnosed with 
MAIS and gynecomastia in males and breast cancer in females. There were 7 
affected members (6 males with MAIS and one female with breast cancer) in the 
present genetic study. All the males of the family had a 46, XY karyotype with a 
male phenotype and all the females in the family had a 46, XX karyotype with a 
female phenotype.  
The special observation of this family was that all the affected males with MAIS 
and gynecomastia were in the left arm of the pedigree whereas the breast cancer 
affected females were in the right arm of the family. More precisely, both arms 
were descendents of the same father of (G1), but one arm (left) was comprised of 
male offspring's with MAIS and their genetic lineage males (i.e. next generation) 
were also affected with MAIS, whereas none of the females in the left arm of the 
pedigree had breast cancer although they are under observation for such a 
development. In the right arm, the daughter of the suspected father (G1) was 
affected with breast cancer and her genetic lineage females also had breast cancer, 
except one, who was under observation for such a development. There was a 
single male in the right arm and he was also under observation for androgen 
related disorders. The family was divided into following three groups:  
(1) Affected members of same lineage [(n = 7) M: 6, F: 1]. 
(2) Unaffected members of the same lineage [(n = 4) M: 2, F: 2]. 
(3) Genetically un-related normal family members (by marriage), who served as 
controls [(n =5) M: 1, F: 4]. 
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Figure 11: Pedigree of family kindred with MAIS and Breast Cancer: Circles and squares indicate Females and Males, respectively. G1, G2, G3 
and G4 indicate the generations. Solid black circles and squares indicate the affected subjects. A solid vertical black line inside the circles and 
squares indicate the unaffected related subjects. Light-shaded circles and squares indicate the controls. Circles and squares with a cross represent 
the deceased subjects and the subjects who refused to participate in the study are indicated by dotted circles and squares. 
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2.3 Extraction of genomic DNA from patient whole blood samples 
Genomic DNA was extracted from whole blood using a standard salting-out 
method as described by Miller et. al., 1988. This method involves salting out of 
the cellular proteins by dehydration and precipitation of DNA  with a saturated 
NaCl solution (Miller et.al., 1988). 
Ten ml of the fresh whole blood was collected in EDTA vacutainer tubes (BD 
Biosciences, South Africa), mixed with 45 ml cold lysis buffer (Appendix B) and 
centrifuged at 2300 rpm for 2 mins. The supernatant was decanted and the pellets 
were resuspended in 20 ml ice cold lysis buffer, incubated on ice for 5 mins, and 
thereafter centrifuged briefly at 2300 rpm for 2 mins at 4°C in a centrifuge. The 
pellet was resuspended in 4 ml of nuclear lysis buffer and 500 µl proteinase K 
which contained 10% SDS (Appendix B) was added. The samples was mixed 
well and incubated at 37 °C in a water bath overnight. 
The next day, 1 ml of a saturated NaCl solution (Appendix B) was added to each 
tube, mixed vigorously and incubated on ice for 5 mins, followed by 
centrifugation at 2300 rpm for 30 mins in a centrifuge. The supernatant was 
transferred into a clean 50 ml tube and the DNA precipitated with 20 ml absolute 
ethanol.  
The samples were incubated at -20°C overnight and centrifuged at 8000 rpm for 
30 mins at 4
0
C. To remove the salt used to precipitate the DNA, the pellets were 
washed with ice cold 70% ethanol, centrifuged at 8000 rpm for 20 mins in a 
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centrifuge and, the DNA pellet air dried at room temperature and the DNA finally 
dissolved in 500 µl TE buffer (Appendix B). 
The purified genomic DNA was quantified using a Nanodrop Spectrophotometer 
ND-1000 (NanoDrop Technologies Inc., Wilmington, Del.). 
2.4 PCR amplification of the coding region of the AR gene 
2.4.1 The design of primers to amplify exons 1 to 8 of AR gene 
Exon 1 is the largest exon of the AR gene. At 1614 bp it constitutes over 58 % of 
the complete AR (2760 bp) gene. Exon 1 is also a guanine and cytosine (GC) rich 
region, since it contains stretches of CAG and GGC triplet repeats. These two 
factors presented a problem when it came to amplifying exon 1 as we were unable 
to amplify one PCR product that could be sequenced with accuracy. The strategy 
adopted was to therefore to amplify exon 1 in two parts designated Part I and Part 
II. Since there was no problem with exons 2-8, they were amplified as a single 
product. 
Based on the most recent reference sequence of the human AR gene (Gene Bank 
ID NM_000044.2, http://androgendb.mcgill.ca/), two sets of primers were 
designed for exon 1, in such a way to cover the whole 1614 bp sequence. The 
resultant products overlap by 220 bps as shown in the figure 12. We designed the 
exon primers for the amplification of each exon using the primer3 software 
(http://primer3.wi.mit.edu/) and these were synthesised by Inqaba Biotech Ltd 
(Pretoria, South Africa). The sequence of the primer pairs for all the exons are 
listed in the table 2. 
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Figure 12: This diagram represents the primer design for exon 1 of the AR gene. 
Exon 1 was amplified in two parts. Part I is shown in pink and amplified by 
primer set 1. Part II is shown in green and amplified by primer set 2. The 
overlapping region of 220 bp is shown in purple.  
 
2.4.2 PCR conditions for amplifying exon1 to exon 8 of the AR  
PCR reactions for amplification of all exons were optimized in a total volume of 
50 µl, containing 2.5 mM of each deoxynucleoside triphosphate (dNTP), 20 µM 
of each set of primers, 1.5 mM MgCl2, 10x PCR buffer, and 50 ng/µl genomic 
DNA. 5U BIOTAQ ™ DNA polymerase was used for all PCR reactions (Bioline 
Ltd, Luckenwalde, Germany), except part II of exon 1, in which, Hotstar Taq 
DNA (QIAGEN) was used. Additionally 5 µl of 5x Q-solution (Qiagen) was used 
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for amplification of exon 1 (part I and part II), according to the manufacturer's 
protocols. Q solution is a proprietary solution recommended for amplification of 
templates containing GC rich sequences which is capable of resolving the 
formation of secondary DNA structures. By influencing the melting behavior of 
DNA, Q solution is able to diminish polymerase failure as a result of the hairpin 
structures and loops caused by high GC content. 
 
Reactions were performed in a thermal cycler (MJ Mini, Bio-Rad) with the 
following reaction conditions: 94 ˚C initial denaturation for 5 min, 94 ˚C 
denaturation for 1 min, annealing for 1 min, 72 ˚C extension for 2 min, for a total 
of 35 cycles, followed by 72 ˚C final extension for 10 mins. The annealing 
temperatures of each PCR reaction are listed in the table 2. All PCRs were 
performed in duplicate and a negative control (no template DNA) was included in 
the PCR analysis to rule out DNA contamination.  
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Table 2: Primers for PCR amplification, annealing temperature and location of each exon on the X chromosome (Gene Bank 
accession # NM_000044.2) 
Exons Primer Sequence 
Location on X chromosome  
(start-end) 
Size of amplicons 
(bp) Annealing Temperature  
Exon 1:Set 1 Forward: 5’-AGAGGAGGCGACAGAGGGAAA-3’  5061-5081 1605 65 ˚C 
  Reverse: 5’-ATGTCTTTAAGGTCAGCGGAGCAG-3’ 6643-6666     
Exon 1:Set 2 Forward: 5’-TGGATGAGGAACAGCAACCT-3’  6443-6463 1533 59 ˚C 
  Reverse: 5’-GGTTGGGGGAGTTGAAGAAT-3’  7957-7976     
Exon 2 Forward: 5'-TGAAGACCTGAGACTTCACTTGCC-3' 104149-104172 311 58 ˚C 
  Reverse: 5'-AATCCTGGGCCCTGAAAGGTTAGT-3' 104437-104460     
Exon 3 Forward: 5'-GACTCTGGAAACTCATTATCAGGTCT-3' 146927-146952 205 60 ˚C 
  Reverse: 5'-AGAGGAAGGAGGAGGAAGAGAAAG-3' 147109-147132     
Exon 4 Forward: 5'-TAGAGTCTGTGACCAGGGAG-3' 172248-172268 525 54 ˚C 
  Reverse: 5'-ATGAAGACTGCCTGAGTTAATG-3' 172752-172773     
Exon 5 Forward: 5'-ACTGCCTCTGCCTCTTCTTCTC-3' 178422-178443 255 58 ˚C 
  Reverse: 5'-TCACTGTCACCCCATCACCATC-3'  178656-178677     
Exon 6  Forward: 5'-ATCAGAGACATTCCCTCTGGGCTT-3' 182728-182752 230 54 ˚C 
  Reverse: 5'-CATTCCCTGCACTTCTAGGCACTT-3' 182935-182958     
Exon 7 Forward: 5'-CCCATTCTGTCTTCATCCCACATC-3' 183770-183793 219 60 ˚C 
  Reverse: 5'-TTCTCCCTGATAAAGCACCCTCCA-3' 183966-183989     
Exon 8 Forward: 5'-CACCTCCTTGTCAACCCTGTTT-3' 184608-184629 615 54 ˚C 
  Reverse: 5'-TCCCCAGATAATCTTAGCTCTC-3' 185202-185223     
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2.4.3 Agarose gel electrophoresis 
Amplified products of each exon were resolved on agarose gels of the appropriate 
volume and concentration, prepared as described in Appendix B. Once completely 
solidified, the agarose gel was immersed fully in an electrophoresis tank 
containing 1x TBE buffer as given in Appendix B. 5 µl of amplified PCR product 
were mixed thoroughly by adding 1µl of 6x Blue/Orange loading Dye (Promega, 
Madison, WI, USA) and were loaded into an agarose gel and electrophoresed at 
~90 to ~100 volts/cm until the bromo phenol blue tracking dye front had migrated 
~75% of the length of the gel. An image of each gel was recorded using the Gel 
Doc XR Imaging System (Bio-Rad). A clear band of the predicted size (given in 
the table 2) of each exon was observed after the gel electrophoresis (see figures 15 
to 22). 
2.5 Analysis of sequencing data of exons 2-8 of the AR gene 
Un-purified PCR products of exons 2-8 were sent to Inqaba Biotechnical 
Industries Ltd (Pretoria, South Africa) for direct DNA sequencing, where 
sequencing was carried out using an ABI 3130XL genetic analyzer, using same 
set of primers as was used for the PCR. Sequences were subjected to a standard 
nucleotide-nucleotide BLAST search (http://www.ncbi.nlm.nih.gov/Blast.cgi) to 
ensure that the amplicons were the human androgen receptor gene. 
The analysis was divided into 3 categories; affected, un-affected and control. 
Sequences were analyzed at the nucleotide level as well as amino acid level, 
nucleotide sequences were converted into amino acid using the ExPASy translator 
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tool. Bioedit and Clustal Omega software's were used for aligning both nucleotide 
and amino acid sequences. The most recent human AR gene (Gene Bank ID 
NM_000044.2) was used for the alignment. 153 nucleotides of exon 2, 117 
nucleotides of exon 3, 288 nucleotides of exon 4, 144 nucleotides of exon 5, 132 
nucleotides of exon 6, 159 nucleotides of exon 7 and 156 nucleotides of exon 8 
were used for the analysis.  
2.6 Analysis of exon 1 
The direct sequencing of exon 1 did not prove successful as it failed to resolve the 
GC rich regions of the two alleles and therefore a cloning strategy was adopted. In 
addition this method would be effective in separating out the parental alleles to 
assist in analyzing the inheritance pattern. Part I and part II of exon 1 were cloned 
into the pGEM®-T easy vector using the T/A cloning kit supplied by the 
(Promega, Madison, WI, USA) and individual clones were subsequently sent for 
sequencing. See the figure 13 and figure 14 in Appendix C for details on the 
pGEM®-T easy vector system, the vector map and multiple cloning site. 
2.6.1 Purification of amplicons of exon 1 (part I and part II) 
The PCR products of exon 1 (part I and II) were resolved on agarose gels of the 
appropriate volume and concentration as mentioned in the Appendix B. 45 µl of 
amplified PCR product were mixed thoroughly by adding 2-3 µl of 6x 
blue/orange loading dye (Promega, Madison, WI, USA) and were loaded into pre-
cast agarose gel wells and electrophoresed at ~90 to ~100 volts/cm until the 
bromo-phenol blue tracking dye front migrated ~75% of the length of the gel. 
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Visualization of DNA bands was carried out by placing the gel on the UV 
Transilluminator (Kodak, Electrophoresis documentation and analysis system), 
with a very low exposure of UV to avoid the formation of pyrimidine dimers. The 
DNA fragments were excised from the agarose gel using a razor blade and 
transferred to previously weighed empty 1.5 ml eppendorfs and weighed again to 
determine the weight of the gel slice, a requirement of the gel purification 
method. The DNA was purified from the agarose gel using the Zymoclean™ Gel 
DNA Recovery Kit (Zymo Research, Germany). All the purification steps were 
performed following the manufacturer’s instructions. 
The purified amplicons of exon 1 (part I and II) were quantified using 
spectrophotometric analysis on a Nanodrop ND-1000 Spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, Del.) and subsequently used in 
ligation reactions. 
2.6.2 Preparation of Chemically Competent Cells 
E. coli bacterial strain DH5 α was made chemically competent using the 
Rubidium Chloride method (Choudhury A et al., 2009). 
A 1000 µl overnight culture of DH5 α was inoculated into 100-500 ml of Psi 
broth (Appendix B). The inoculated Psi broth was incubated at 37 ºC and shaken 
at 235 rpm in a orbital shaker incubator (LM-510, Sci-Lab Technology Co. Ltd. 
China) until an optical density at 600 (OD 600) reached 0.6 - 0.7. Following 
incubation of this culture on ice for 15 mins, a 3 ml aliquot was centrifuged at 3-
5000 rpm for 5 mins using Sorvall SS-34 rotor. The pellet was resuspended with 
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40-400 ml TfbI buffer (Appendix B) and incubated on ice for 15 mins and re-
centrifuged. The pellets was then re-suspended in 0.04 volumes TfbII (Appendix 
B), incubated on ice for 15 mins and then snap frozen in liquid nitrogen for 
storage at -70 ºC. 
2.6.3 Ligation reactions 
Ligation reactions were set up in a 3:1, insert: vector molar ratio using the 
following formula  
 
All the ligation reactions were performed according to manufacturer's instruction 
(Promega, Madison, WI, USA). See table 3 (Appendix B) for the ligation reaction 
conditions. Reactions included a positive control (supplied by manufacturer) and 
no insert control. The ligation reactions were incubated at 4 ºC overnight to 
produce maximum number of transformants. 
2.6.4 Transformation of ligation products into DH5 α cells using heat shock 
We used high efficiency competent cells, DH5 α cells with a transformation 
efficiency of 1X10
8
cfu/µg DNA for transformations in order to obtain a 
reasonable number of colonies. 2-3 µl of ligated products were transformed into 
50 µl DH5 α chemically competent cells, as described (Kushner,1978). To ensure 
that the transformation results were unambiguous and to assess the efficiency of 
ng of vector  X  kb size of insert  
X 
kb size of vector   
insert : vector molar ratio = ng of insert 
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ligation numerous controls were prepared and included in the transformation 
protocol. As a transformation positive control, a known amount of closed circular 
(uncut) plasmid was used in the transformation. All the steps were carried out on 
ice. Two µl of each ligated product was added into a 1.5 ml eppendorf tube 
containing 50 µl of previously thawed DH5α chemically competent cells. The 
tubes were kept on ice for 20 mins to allow the DNA to precipitate  and  thereafter 
the bacteria was heat shocked in a dry bath at 42 ºC for 45-50 sec and then 
immediately chilled on ice for 2-5 mins. The transformed cells were resuspended 
in 950 µl of room temperature SOC medium (Appendix B) and were incubated at 
37 ºC with ~150 rpm agitation for 90 mins in an orbital shaker incubator (LM-
510, Sci-Lab Technology Co. Ltd. China). The cells were pelleted by 
centrifugation at 1000 rpm for 5 mins. The upper 750 µl of SOC medium was 
discarded and the pellet was resuspended in the remaining 250 µl of SOC 
medium. For each ligation reaction two plates of LB ampicillin/IPTG/ X-gal were 
used. IPTG, in conjunction with X-gal, was used to detect β-galactosidase activity 
in order to differentiate recombinants from non-recombinants with vector 
containing the lac Z α-peptide gene) (Promega, Madison, WI, USA) and two 
plates of LB ampicillin/IPTG/X-gal were used for determining the transformation 
efficiency. All the plates were prepared at room temperature (Appendix B). 
Usually 100 µl - 150 µl of the transformation mix was plated onto each plate and 
they were incubated inverted at 37 ºC overnight in an incubator (Amersham 
Biosciences, Washington, USA). 
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2.7 Screening of transformants for inserts 
Successful cloning of an insert into the pGEM®-T easy vector interrupted the 
coding sequence of β-galactosidase gene and the recombinant clones were 
identified by color screening on LB ampicillin/IPTG/X-gal plates. The PCR 
products cloned into the vectors significantly affected the ratio of blue: white 
colonies. The colonies containing the inserted PCR product produced white 
colonies. We screened 10 to 15 white colonies for each ligation reaction 
corresponding to a PCR product of exon 1 part I and II for each patients genomic 
DNA as described in the following steps. 
2.7.1 Plasmid extraction  
For screening of transformants for inserts, 10 to 15 white colonies of each sample 
for both part I and part II of exon 1, were inoculated in a 15 ml tubes containing 
1-5 ml of Luria broth with 50 mg/ml ampicillin. The tubes were incubated at 37 
ºC and shaken at 230-250 rpm in an orbital shaker incubator (LM-510, Sci-Lab 
Technology Co. Ltd. China) for about 12 hrs-16 hrs. The next day bacterial 
cultures were harvested by centrifugation at 6000 rpm for 2 mins at room 
temperature. The supernatant was decanted and all traces of remaining LB 
medium removed. High quality plasmid DNA was extracted using Gene JET 
plasmid-mini prep kit which is based on the SDS/alkaline lysis method (Promega, 
Madison, WI, USA). 
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2.8 Checking of positive clones by restriction digestion analysis  
All isolated plasmid DNA was subjected to restriction digestion analysis to screen 
for and identify positive clones. The pGEM
®
-T easy vector contains numerous 
unique restriction sites within the multiple cloning sites. See figure 14 for the 
sequence and multiple cloning site of the vector (Appendix C). Plasmid restriction 
was carried out using the Fast digest enzyme Not I (Fermentas, USA). The 
reaction was set up for 10 µl and incubated at 37 ˚C in a dry heat block for 50-60 
mins. Refer the table 4 for restriction digestion reaction conditions (Appendix B). 
The thermal inactivation of the restriction enzyme Not I was achieved by 
incubating the reaction at 80 ˚C for 5 mins. All the steps were performed in 
accordance to the manufacturer’s instructions. An uncut control (DNA without 
enzyme) was included in the analysis to compare digest patterns and to identify 
bands corresponding to uncut vector. The entire restriction reaction was resolved 
on a 1% agarose gel (Appendix B) as described previously (Section 2.4.3). 
Images of the gels were recorded using the Gel Doc XR Imaging System (Bio-
Rad) and used to identify the plasmids containing  insert. 
2.9 Sequencing of plasmid DNA of exon 1 (part I and part II) and Analysis 
Six to eight positive clones of each sample of exon 1 (part I and part II) were 
selected and sent for sequencing. The plasmid DNA was sequenced using the ABI 
3730xl DNA analyzer (Applied Biosystems, MACROGEN, Seoul, Korea) using  
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two universal primers, the T7 forward promoter and the M13 reverse primer of 
the pGEM®-T easy vector. 
Sequences were subjected to a standard nucleotide-nucleotide BLAST search 
(http://www.ncbi.nlm.nih.gov/Blast.cgi) to ensure that the amplicons amplified 
were the human androgen receptor gene, and 1614 nucleotides of exon 1 was used 
for the analysis, carried out as described before in Section 2.5. 
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CHAPTER 3 
3. RESULTS  
3.1 Amplification of exons 1-8 of androgen receptor gene, sequencing and 
analysis 
Genomic DNA was extracted from all sixteen members of the family who agreed 
to participate in the genetic study. Each exon of the AR gene was amplified 
successfully as a single PCR product, using single set of primer listed in the (table 
2), except for the exon 1, which was amplified as two PCR products (part I and 
part II) using 2 sets of primer (listed in the table 2). Amplified products of each 
exon were gel electrophoresed and an image of each gel was recorded. A clear 
band of the predicted size (given in table 2) of each exon was observed after the 
gel electrophoresis. A gel picture of each exon is shown corresponding from 
figure 15 to figure 22.  
Amplified products of exons 2-8 were sequenced directly, using the same set of 
primers, as were used for the PCR (table 2). The amplified products of exon 1 
(part I and II) were cloned, as described in the section 3.2 below. 
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Figure 15: Amplification of exon 1 of AR gene, Lane 1-6 is positive 
amplification of a 1600 bp DNA band, M=1kb DNA ladder and N=negative 
control. 
 
 
Figure 16: Amplification of exon 2 of AR gene, Lane 1-16 is positive 
amplification of a 312 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 N 
500bp 
400bp 
300bp 
200bp 
312 bp 
M 1 2 3 4 5 6 N 
250bp 
500bp 
750bp 
1000bp 
1500bp 
2000bp 
3000bp 
1605 bp 
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Figure 17: Amplification of exon 3 of AR gene, Lane 1-7 is positive 
amplification of a 206 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
 
 
Figure 18: Amplification of exon 4 of AR gene, Lane 1-16 is positive 
amplification of 525 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
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Figure 19: Amplification of exon 5 of AR gene, Lane 1-16 is positive 
amplification of a 256 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
 
 
 
Figure 20: Amplification of exon 6 of AR gene, except lane 7 and 11 from lane 
1-17 is positive amplification of a 230 bp DNA band, M = 100 bp DNA ladder 
and N = negative control.  
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Figure 21: Amplification of exon 7 of AR gene, Lane 1-16 is positive 
amplification of a 220 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
 
 
Figure 22: Amplification of exon 8 of AR gene, Lane 1-16 is positive 
amplification of a 616 bp DNA band, M = 100 bp DNA ladder and N = negative 
control. 
 
616bp 
100bp 
200bp 
300bp 
400bp 
500bp 
600bp 
700bp 
800bp 
900bp 
1000bp 
1500bp 
M  1    2   3   4   5    6   7   8   9  10 11 12 13 14 15  16 N 
M   1   2   3   4   5   6  7  8   9   10  11 12 13 14 15 16 17 N 
500bp 
300bp 
200bp 
100bp 
220bp 
65 
 
 
3.2 Cloning of part I and II of exon 1 of AR gene 
The PCR products of exon 1 (part I and II), of all the 16 members of the family 
were gel purified, quantified and ligated in 3:1, insert: vector ratio into a pGEM-T 
easy vector individually. Following transformation positive clones were checked 
by restriction enzyme digestion using Fast digest enzyme Not I. Digestion with 
Not I cuts the vector twice to produce to two clear bands: one band corresponding 
to vector sequence (3015 bp) and another the insert (of either 1605 bp for part I 
and 1533 bp for part II of exon 1). An image of each gel was recorded for both 
part I and II of exon 1 and is shown in the figures 23 and 24 respectively. 
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Figure 23: M = 1Kb gene ruler, Restriction mapping is done by Not I. Positive 
clone (of part I of exon 1) is shown by a 1605 bp DNA band and the pGEM-T 
easy vector DNA band is 3015 bp. UC= uncut. 
 
Figure 24: M=1Kb Gene ruler, Not I Restriction map of the pGEM vector. 
Positive clone (of part II of exon 1) is shown by 1533 bp DNA band and the 
pGEM vector DNA band is shown by 3015 bp and UC= uncut. 
 
3.3 Sequencing of plasmid DNA of exon 1 (part I and part II) and Analysis 
Six to eight positive clones of each sample of exon 1 (part I and part II) were 
sequenced using the two universal primers, T7 promoter forward and M13 reverse 
primer of the pGEM®-T easy vector and each part analyzed separately as 
described in section 2.5. 
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3.4 Results of CAG repeat length (Poly-glutamine tract variations) 
3.4.1 Defining and dividing CAG repeat length of the androgen receptor gene 
The length of poly Q varies from 14 to 35 repeats, with an average of 21 ± 2 
repeats (Irvine et al., 1995). Analysis of CAG repeat length was divided into 3 
categories based on their length as follows; 
 (CAG)n repeat length < 23 were classified as short (S). 
 (CAG)n repeat length = 23 were classified as wild type (WT).  
 (CAG)n repeat length > 23 were classified as long (L). 
The CAG variation and superimposed poly-glutamine stretch among affected, 
unaffected and control individuals are shown in the table 5 and 5a. 
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Table 5: Representation of the addition and deletions of the Poly-glutamine tract identified in all 16 members of the family. M stand 
for Male and F stand for Female. Q stands for amino acid glutamine. Empty triangle represents deletion and solid black downward 
triangle represents addition of amino acid. ID- identifies each family member on the pedigree. 
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Figure 11 (a) Table 6 superimposed on pedigree as given in figure 11 Addition and deletions 
of the Poly-glutamine tract identified in all 16 members of the family.  
 
 
Figure 11a: Pedigree of family kindred with MAIS and Breast Cancer and correlation with 
poly-glutamine CAG repeat length identified in present study: Circles and squares indicate 
Females and Males, respectively. G1, G2, G3 and G4 indicate the generations. Solid black circles 
and squares indicate the affected subjects. A solid vertical black line inside the circles and squares 
indicate the unaffected family members. Light-shaded circles and squares indicate the controls. 
Circles and squares with a cross represent the deceased subjects and the subjects who refused to 
participate in the study are indicated by dotted circles and squares. There are two main arms of 
the study, left arm (capital alphabet) and right arm (small letters) and these two arms bifurcates in 
G2. Right arm (small letters) family members were affected with breast cancer and in left arm 
(capital alphabet) family members are affected with MAIS, gynecomytia.  The number over each 
subject indicates the length of the CAG repeats identified in the present study     
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3.4.2 Analysis of results of poly-glutamine stretch within the exon 1 region of 
the AR gene 
Four generations, with a total of 16 members of the family, which were 
segregated into two arms i.e. MAIS affected males in the MAIS arm and breast 
cancer affected females in the BC arm, were placed into three groups:  
(1) Affected members of same lineage [(n = 7) (M: 6;  F: 1)], six males (‘C’, ‘E’, 
‘H’, ‘I’, ‘K’, ‘L’) had MAIS and gynecomastia, and one female (‘d') had breast 
cancer. 
(2) Unaffected members of the same lineage, who were under observation [(n = 4) 
(M: 2 F: 2)], two males (‘B’ and ‘b’) and two females (‘F’ and ‘c’). 
(3) Unrelated normal members, which served as controls [(n =5) (M: 1 F: 4)] were 
a single male (‘a’) and four females (‘A’, ‘D’, ‘G’ and ‘J’). 
3.4.3 Detection of variation in the poly-glutamine tract (CAG-repeat). 
The variations of poly-glutamine stretch among affected members were (S: 3, L: 
4). A short poly Q stretch was observed in three males affected with MAIS (‘C’, 
‘H’, and ‘I’), whereas the sequences of the remaining four affected members 
revealed long poly Q stretch, of which three were males (‘E’, ‘K’ and ‘L’) with 
MAIS and one female (‘d’) with breast cancer. Based on these results, it seems 
that poly Q stretch is variable and is not particularly associated with MAIS. Since 
there was a single female with breast cancer, we tried to correlate the results of 
poly Q stretch with controls and unaffected members of the family. On analysis, 
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the CAG repeat length of un-affected family members (n = 4) revealed wild type 
CAG repeat sequences in one, CAG repeat was longer in 2 and shorter in 1 
member (WT: 1, L: 2, S:1). Among the four unaffected members, one male ‘b’ 
and one female ‘c’ were identified with a longer poly Q stretch. One male ‘B’ was 
identified with a shorter poly Q stretch and one female ‘F’ was identified as  
completely wild type. Of the five controls in the family, we identified one female 
(‘D’) with a short poly Q stretch, another female with a long poly Q stretch (‘G’) 
and three controls including two females (‘A’ and ‘J’) and one male (‘a’) were 
completely wild type. Interestingly, in the 3
rd
 generation all affected members 
were identified with only S CAG repeats and in the 4
th
 generation all the affected 
members and two unaffected members had L CAG repeat.  
3.4.4 (a) Poly-glutamine stretch among the 2nd generation: There were only 2 
members in the 2nd generation of the MAIS arm, a single control female and a 
single unaffected normal male. The control female ('A') was completely wild type, 
whereas an unaffected male 'B' showed a S CAG repeat,. In the BC arm, two 
members (a normal male and breast cancer affected female) died and were not 
included in the study. 
3.4.5 (b) Poly-glutamine stretch among the 3rd generation: In the 3
rd
 generation, 
there were 6 members (3 affected males and 3 control females) in the MAIS arm 
of the family.  Poly-glutamine repeat analysis revealed CAG S repeats among all 
three MAIS affected males ('C', 'H' and 'I'), and among controls, one of each 
female ('J'), ('D') and ('G')  control were identified as WT, CAG S and CAG L, 
whereas in the BC arm there was only a single control male ('a') member who was 
72 
 
completely WT and his partner, who died as a result of  breast cancer and was not 
included in the study. 
3.4.6 (c) Poly-glutamine stretch among the 4th generation: In the 4
th
 generation, 
there were 4 members (3 affected males and a single unaffected female) in the 
MAIS arm of the family. Poly-glutamine analysis revealed CAG L repeat among 
all 3 MAIS affected males ('E', 'K' and 'L'), and a single unaffected female ('F') 
was completely WT, whereas in the BC arm, there were 3 members, 1 affected 
female (d'), 1 unaffected female ('c') and 1 unaffected male ('b'). All of them 
showed CAG L repeat and they were of the same genetic lineage. Refer to table 5. 
3.5 Results of GGN repeat length (Poly-glycine tract variations) 
3.5.1 Defining and dividing GGN repeat length of the androgen receptor gene 
For the length of the poly-G repeats, the consensus appears to be that normal 
phenotypic males have 10 to 30 repeats in most of the population (Rajender et al., 
2007). The functional consequences of variations in GGN repeat are less clear, the 
deletion of the poly-glycine tract reduces AR transcriptional activity in transient 
transfection assay (Gao et al., 1996). AR GGN repeat length polymorphism has 
been less studied in MAIS and BC. Variation in length can be associated with 
prostate cancer, but any relationships between the repeat length and disease 
characteristics are not clear (Montgomery et al., 2001; Edwards et al., 1999). 
Analysis of GGN repeat length was also divided into 3 categories, based on their 
length as given below: 
73 
 
 (GGN)n repeat length < 23 were classified as short (S). 
 (GGN)n repeat length = 23 were classified as wild type (WT) and 
 (GGN)n repeat length > 23 were classified as long (L). 
The GGN variations and superimposition of poly-glycine stretch among the 
affected, unaffected and controls are shown in the table 6 and 6a. 
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Table 6: Representation of addition and deletions of the poly-glycine tract in all 16 members of the family. M stand for Male and F 
stand for Female. G stands for amino acid glycine. Empty triangle represents deletion and solid black downward triangle represents 
addition of amino acid. ID- identifies each family member on the pedigree. 
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Figure 11 (b) Table 6 superimposed on pedigree as given in figure 11: Addition and deletions 
of the Poly-glycine tract identified in all 16 members of the family.  
 
 
Figure 11b: Pedigree of family kindred with MAIS and Breast Cancer and correlation with poly-
glycine GGN repeat length identified in present study: Circles and squares indicate Females and Males, 
respectively. G1, G2, G3 and G4 indicate the generations. Solid black circles and squares indicate the 
affected subjects. A solid vertical black line inside the circles and squares indicate the unaffected family 
members. Light-shaded circles and squares indicate the controls. Circles and squares with a cross 
represent the deceased subjects and the subjects who refused to participate in the study are indicated by 
dotted circles and squares. There are two main arms of the study, left arm (capital alphabet) and right arm 
(small letters) and these two arms bifurcates in G2. Right arm (small letters) family members were 
affected with breast cancer and in left arm (capital alphabet) family members are affected with MAIS, 
gynecomytia. The number over each subject indicates the length of the GGN repeats identified in the 
present study     
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3.5.2 Analysis of results of the poly-glycine stretch within the exon 1 region of 
the AR gene 
We have identified, that the androgen receptor (GGN)n variations also differed 
among individuals and generations. Data analysis suggests that S GGN repeats 
[12/16 (75%), A:6, U:3, C:3] in a majority of the family members; however, only 
one [1/16 (6%) , A:0, U:0, C:1] of the family member showed L GGN repeats and 
three [3/16 (19%), A:1, U:1, C:1] of the family members showed WT GGN 
repeats. 
3.5.3 Generation specific analysis of Poly-glycine tract (GGN-repeat) 
3.5.3 (a) Poly-glycine stretch among the 2nd generation: Among two members 
of the MAIS arm in the 2nd generation, a single control female ('A') was 
identified as GGN S and a single unaffected normal male ('B') also showed GGN 
S repeat.  
3.5.4 (b) Poly-glycine stretch among the 3rd generation: The three affected 
males ('C', 'H' and 'I') of the MAIS arm revealed GGN S repeat. Whereas among 
the 3 control females of the MAIS arm, one ('G') was GGN L, one ('J') was GGN 
S and the other female control ('D') was identified as WT. However, a single 
control male ('a') of the BC arm also showed a GGN S repeat and his partner, who 
died as a result of breast cancer, was not included in the study. 
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3.5.5 (c) Poly-glycine stretch among the 4th generation : In the 4th generation, 
among the 3 affected males of the MAIS arm, two affected males ('K' and 'L') 
showed GGN S repeat and the other affected male ('E') was WT. A single 
unaffected female ('F') of the MAIS arm was identified as GGN S, whereas, in the 
BC arm, 1 affected female ('d') and 1 unaffected male ('b') were identified as 
GGN S, and the unaffected female ('c') was completely WT. 
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CHAPTER 4 
4. Results of androgen receptor gene point mutations 
4.1 Analysis of sequencing data of all the exons of the AR gene 
Analysis of point mutations was conducted on the complete androgen receptor 
gene covering all the exons (1-8). We analyzed 1614 nucleotides of exon 1, 153 
nucleotides of exon 2, 117 nucleotides of exon 3, 288 nucleotides of exon 4, 144 
nucleotides of exon 5, 132 nucleotides of exon 6, 159 nucleotides of exon 7 and 
153 nucleotides of exon 8. The 16 members of the family with four generations 
were grouped into three as described in section 3.4.2. 
All the nucleotide changes detected were translated into amino acids using the 
software ExPASy translator tool. The aligning of the nucleotide sequences and the 
amino acid sequences were carried out using Bioedit and Clustal Omega 
software's. The recent human AR gene sequence from the Gene Bank ID 
NM_000044.2 was used as a reference. 
4.2 Analysis of exons 2-8 of androgen receptor gene 
No mutations were identified in any of the family members in the exons 2-8 
region of the androgen receptor gene. All sequences were completely wild type 
and well conserved. 
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4.3 Identification of point mutations in exon 1 
We analyzed 5-6 clones for part I and II of exon 1 in all 16 members of the 
family. Each mutation reported were identified in at least 2 of the clones for each 
member. None of the mutations were identified in all 6 of the clones, however a 
few of the mutations were present ranging from 33.3%-66.6% of the clones. 
Mutational analysis revealed several important AR gene mutations in 16 members 
of the family. A total of 43 single nucleotide substitutions in exon 1 region were 
identified. Based on the analysis; we divided these mutations into two parts: 
(1) Novel mutations and 
(2) Previously reported mutations.  
All the mutations were checked and matched with the updated version of the 
McGill University androgen receptor mutation database 
http://androgendb.mcgill.ca, (Gottlieb et al., 2012). The mutations obtained in the 
control members were matched with the reports of normal individuals with mutations 
in the AR gene of the ARDB data base. In addition, we also cross checked all the 
mutations identified in the present study with mutations reported in the PubMed 
literature database of the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/pubmed).  
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Of these 43 point mutations, we classified 30 as novel mutations and 13 were 
previously reported. Furthermore, the distribution of each mutation among the 
members of the family is described below and is based on the clinical state and 
genetic lineage.  
The distribution of all the novel and reported mutations of the affected members 
of the family were/are listed in detail in the table 7 and those of unaffected and 
control members of the family were listed in the table 7a. 
Except for three mutations, none of the mutations were common among any of the 
family members; however, some of the mutations were coexisting. ‘Common’ 
was defined as a similar mutation at the same position in two different members 
and the ‘co-existing’ mutations could be double, triple and quadruple mutations 
identified in a single member. 
81 
 
Table: 7 Details of the complete novel and previously reported point mutations in affected members of the family. An 
ID code has been assigned for each affected member and is given in the extreme left column. M is Male and F is 
Female.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Member code 
(category) 
Sex Novel mutations at 
amino acid level 
(clones) 
Novel mutations at 
nucleotide  level 
Reported mutations 
at amino acid level 
 Reported 
mutations 
at nucleotide 
level 
References of reported 
mutations 
C 
(MAIS Affected) 
M L 108 P(2) 
E 113 K (4) 
 
CTG→CCG 
GAA→AAA 
 
E 155 G (4) 
E 289 G (3) 
Q 445 R (3) 
 
 
 
GAG →GGG 
GAA→GGA 
CAG→CGG 
Copelli et al., 
Holterhaus et al., 
Gottlieb et al., 
E 
( MAIS Affected) 
M T 231 I (2) ACC→ATC G  456 D (3)  GGT→GAT Steinkamp et al., 
 
H 
( MAIS Affected) 
M Q 78 R (4) 
E 187 G (3) 
L 345 P (3) 
CAG→CGG 
GAG→GGG 
CTG→CCG 
   Novel Mutation 
I 
( MAIS Affected) 
M T 105 I (5) 
C 240 R (2) 
ACA→ATA 
TGT→CGT 
   Novel Mutation 
K 
( MAIS Affected) 
M E 32 V  (2) 
Q 360 R (3) 
R 386 C (3) 
GAA→GTA 
CAG→CGG 
CGC→TGC 
S 221 F (2)  TCC→TTC Audi et al., 
 
L 
( MAIS Affected) 
M N 25 S (4) 
L 347 F (4) 
AAT→AGT 
CTC→TTC 
   Novel Mutation 
d 
(Breast cancer affected) 
F V 132 A (3) 
V 245 M (4) 
W 527 R (2) 
M 528 V (3) 
GTC→GCC 
GTG→ATG 
TGG→CGG 
ATG→GTG 
   Novel Mutation 
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Table: 7a Details of the complete novel and previously reported point mutations in unaffected and control members of the family. An ID code has 
been assigned for each affected member and is given in the extreme left column. M is Male and F is Female. 
 
 
 
 
 
  
 
 
Member code 
(category) 
Sex Novel mutations 
at amino acid 
level (clones) 
Novel mutations at 
nucleotide  level 
Reported 
mutations at amino 
acid level 
Reported 
mutations 
at nucleotide level 
References of reported 
mutations 
B 
(Unaffected) 
M P 153 L  (2) 
L 389 P (3) 
CCG→CTG 
CTG→CCG 
  Novel Mutation 
F 
(Unaffected) 
F Q 72 R (3) 
Q 78 R (3) 
G 326 D (4) 
CAG→ CGG 
CAG→ CGG 
GGC→GAC 
T 440 A (4) ACA→GCA Steinkamp et al., 
b 
(Unaffected) 
M M 191 T (4) ATG→ACG Q 28 Stop (3) 
E 442 K (4) 
CAG→TAG 
GAA→AAA 
Katayama et al., 
Sun et al., &  Luo et al., 
c 
(Unaffected) 
F G 173 S (3) 
P 422 S (2) 
GGC→AGC 
CCC→TCC 
Y 225 C (3) 
G 525 D (4) 
TAC→TGC 
GGC→GAC 
Hannema et al., 
Hyytinen et al., 
A 
(Control) 
F Complete wild Complete wild Complete wild Complete wild Complete wild 
D 
( Control) 
F   Y 481 C (4) 
T 82 A (3) 
TAC→TGC 
ACT→GCT 
Gottlieb et al ; Hannema et al.,& 
Yeh et al., 
Philibert et al., 
G 
(Control) 
F Q 79 R (3) 
A 372 T (4) 
CAG→CGG 
GCC→ACC 
  Novel Mutation 
J 
(Control) 
F V 33 A (3) 
Q 98 R (4) 
GTG→GCG 
CAA→CGA 
  Novel Mutation 
 
a 
(Control) 
M P 49 L (3) 
Q 79 R (4) 
S 361 G (3) 
CCT→CTT 
CAG→CGG 
AGT→GGT 
Q 488 R (3) 
E 155 G (3) 
CAG→CGG 
GAG→GGG 
 
Boehmer et al., 
Copelli et al., 
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4.3.1 Point mutations identified in affected members 
In affected members of the pedigree (n=7) we identified a total of 22 point 
mutations, of which 17 mutations were novel and 5 were previously reported 
mutations. Of the 17 novel mutations, 13 were present in 6 of the MAIS affected 
males: L108P (CTG→CCG), E113K (GAA→AAA), T231I (ACC→ATC), Q78R 
(CAG→CGG), E187G (GAG→GGG), L345P (CTG→CCG), T105I 
(ACA→ATA), C240R (TGT→CGT), E32V (GAA→GTA), Q360R 
(CAG→CGG), R386C (CGC→TGC), N25S (AAT→AGT) and L347F 
(CTC→TTC). 
There are five previously reported mutations which were found in these affected 
males at the position E155G (GAG→GGG), E289G (GAA→GGA), Q445R 
(CAG→CGG), G456D (GGT→GAT) and S221F (TCC→TTC). 
Four novel mutations were identified in the breast cancer affected female at the 
positions V132A(GTC→GCC), V245M(GTG→ATG), W527R(TGG→CGG) 
and M528V(ATG→GTG); however none of the mutations were previously 
reported. 
4.3.2 Point mutations identified in AF-1 domain of exon 1 in affected members 
Interestingly, four mutations (3 novel and 1 reported mutations) were identified in 
tightly conserved residues (aa 224-258) of the activation function-1 (AF-1) 
domain of AR exon1. The three novel mutations were reported as one each in 
three patients. One unreported mutation was also present in a genetically related 
unaffected member in this highly conserved AF-1 domain. Of the three patients 
84 
 
two were affected with MAIS and the third was the female who developed breast 
cancer. Analysis revealed mutations at positions T231I and C240R in the two 
affected males ('E' and 'I') with MAIS and gynecomastia and a single mutation at 
position V245M was identified the female ('d'). The single mutation in the 
genetically related unaffected family member was at the position Y225C 
(unaffected female 'c'). The position of these mutations is shown in the figure 25. 
Electropherograms of all novel mutations identified in affected members are 
shown in the figures 26 to 41 (Appendix D) and those of reported mutations are 
shown in the figures 42 to 46, respectively in Appendix D. 
 
Figure: 25 Highly conserved region of AF-I domain of exon 1, lies between the 
aa 224-258. Three affected members (M:2, F:1) ‘d’, ’E’, ‘I’  and one unaffected 
female ‘c’ showed mutation with in this region at the position T231I, C240R, 
V245M and Y225C showed in black font. 
 
224 25
8 
aa 224-258 highly conserved  
region of   AF-I domain of exon 1 
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CHAPTER 5 
5. DISCUSSION 
5.1 Poly-glutamine tract variations in the androgen receptor gene  
The family described here is unique in that there is segregation of MAIS and 
breast cancer in different lines of the pedigree and to our knowledge this has not 
been reported previously. The clinical features and characteristics of the MAIS 
and breast cancer in the family together with mild infertility-related issues 
dictated that we explore the AR gene, and in particular to assess the CAG and 
GGN tracts and analyze the coding sequence of the AR gene for possible disease 
association. Data on Kennedy’s disease was of particular interest to us in that 
Kennedy's disease was clinically characterized by androgen insensitivity together 
with spinal bulbar muscular atrophy (SBMA) and has been definitively linked to 
the expansion of CAG repeat of exon 1 of AR gene. The expansions of the CAG 
repeat regions in Kennedy’s disease are significant and exceeded 40 (ranges 37 to 
64).  
Taken together our data analysis has shown longer than 23 CAG repeats in many 
of the family members [7/16 (44%), A: 4, U: 2, C: 1]. However, a few [5/16 
(31%), A: 3, U: 1, C: 1] of the family members showed shorter CAG repeats as 
well. Interestingly, only the 2nd generation unaffected male and 3rd generation 
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affected males showed the shorter CAG repeats and in the 4th generation all 
affected members had longer CAG repeat. 
In this study the androgen receptor gene of unaffected members of the family was 
also analyzed and we found that in two of the unaffected members had increased 
length of the CAG repeats Furthermore, the CAG repeat length was increased in 
the single female with breast cancer. 
A few of the studies from the American population has demonstrated a higher 
association of disease risk with longer CAG repeats in individuals having a 
positive family history of breast cancer (Haiman et al., 2002; Wang et al., 2005b). 
Similarly, in a study from Québec a relationship between the long CAG repeat 
and breast cancer (Giguere et al., 2001) was also demonstrated. However two 
studies on Australian women (Spurdle et al., 1999; Spurdle et al., 2005) and two 
on Israeli women (Kadouri et al., 2001; Dagan et al., 2002) reported no 
association between the repeat length and disease risk. In contrast, a few studies 
have reported the inverse correlation (De Abreu et al., 2007; Tsezou et al., 2008). 
All the findings above strongly suggest that CAG repeat length exhibits 
association with breast cancer in a population/region-specific manner. 
Unfortunately in this study in the affected male family members only minor CAG 
extensions were found, and we found no significant expansion (>40) of the CAG 
repeat length. The point to be observed in this family is that the majority of the 
family members (including affected, unaffected and controls) were found to have 
variation, either longer or shorter CAG repeats. Most importantly however was 
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that none of the affected members were found to have the normal CAG repeat 
length.  
These results therefore show an indeterminate association of CAG repeats with 
MAIS and BC in this family. However since the entire 2nd and 3rd generation 
males were found to have reduced CAG repeat lengths we postulate that there 
could be generation specific modulation of AR. One study conducted on nurses 
(Haiman et al., 2002) found no association between the long AR alleles with 
increased breast cancer risk, but when the study was conducted specifically on 
those women with a first degree family history of breast cancer, an increased risk 
of disease was observed (Nicolas Diaz-Chico et al., 2007; Sasaki et al., 2003).  
An inverse- correlation between the CAG repeat length and AR action has been 
demonstrated in in vitro studies (Chamberlain et al., 1994; Kazemi-Esfarjani et 
al., 1995). Furthermore, additional studies showed an inverse-correlation among 
the CAG repeat length and the transactivation activity of the AR (Morales et al., 
2000; Zinn et al., 2005; Kamischke et al., 2003). There is also evidence that in 
patients with Kennedy’s disease, an expansion of repeat length does not 
necessarily occur. Indeed the pedigree described by Ikezoe et al., (Ikezoe et al., 
1999) supports this observation.  
Based on our observations we found an extended CAG repeat in one of the 
unrelated control family members and we speculate that this female may 
independently have an increased risk of breast cancer.  
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5.2 Poly-glycine tract variations in the androgen receptor gene  
The AR GGN repeat length polymorphism has not been extensively studied in 
MAIS and BC patients. In this study shorter GGN repeats were identified in the 
majority of members. The distribution was [12/16 (75%), A:6, U:3, C:3] Only one 
[1/16 (6%), A:0, U:0, C:1] of the family members showed a L GGN repeat, and 
three members of the family members showed WT GGN repeats, [3/16 (19%), 
A:1, U:1, C:1]. Our data suggests an association of shorter GGN repeat with the 
disease, however, when the repeat length of all the family members were 
considered collectively; there were differences amongst the affected, unaffected 
and control members that made it very difficult to come to a definite conclusion 
on the role of GGN length in this family.  
Several other studies have also failed to determine the relationship between GGN 
repeat length and disease characteristics (Edwards et al., 1999; Montgomery et 
al., 2001; Stanford et al., 1997; Platz et al., 1998; Kristiansen et al., 2002). The 
significant association of GGN repeat length and breast cancer in women before 
the age of 45 was supported by only a few studies (Dunning et al., 1999; Kadouri 
et al., 2001; Suter et al., 2003)  
Moreover, earlier studies, on the distribution of GGN repeat length, among 
infertile men found no difference between infertile men and the general 
population (Lundin et al., 2006; Ferlin et al., 2007; Tut et al., 1997). The 
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functional consequences of variations in GGN repeat are therefore less clear. One 
of the studies reported that deletion of the poly-glycine tract could reduce AR 
transcriptional activity in transient transfections assay (Gao et al., 1996). In 
addition investigation of an association between GGN repeats and other diseases, 
specifically prostate cancer, have also produced inconsistent results. Although it 
seems that short GGN repeat length increases the risk of the disease, no clear 
conclusions were drawn from any of the previous studies either (Irvine et al., 
1995; Hakimi et al., 1997; Chang et al., 2002; Cheng et al., 2002; Hsing et al., 
2000; Edwards et al., 1999). One population based study from China had 
observed the combined effect of poly glutamine and poly glycine effects on 
prostate cancer and concluded that a shorter CAG together with a shorter GGN 
repeat length are associated with prostate cancer (Ann W Hsing et al., 2000). 
Shorter poly-G and poly Q repeats result in higher receptor activity of AR that 
inhibits the growth of the steroid related tissues; in contrast, longer poly Q and 
poly-G repeat lengths induce decreases in the trans-activation function in the AR 
receptor and are highly associated with cancers such as breast (Yu et al., 2000; 
Suter et al., 2003), endometrial (Young et al., 2000; Rodriguez et al., 2006), and 
ovarian cancers (Schildkraut et al., 2007; Spurdle et al., 2000). When we 
analyzed the results in generation specific manner, we still reached same 
conclusion of the indetermination association of GGN repeat with the disease.  
5.3 Point Mutations in Androgen Receptor Gene  
More than 800 mutations of AIS have been described in the androgen receptor 
database (http://androgendb.mcgill.ca) and the increasing number of new 
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mutations in different clinical categories of patients, and their importance, is an 
area of intense research (Gottlieb et al., 2012). In this study we have identified a 
total of 43 point mutations of which 30 were novel and 13 were previously 
reported. Four mutations were identified in most conserved AF-1 region of NTD 
in AR gene. The distribution of all these mutations were variable among the 16 
members of the family and no specific pattern of inheritance of mutation, or 
familial clustering of mutations were observed; except for the existence of three 
common mutations (described in detail in the next paragraph). 
On review of the literature and correlating all the 13 recurrent mutations of the 
present study with earlier reports we found that all of them were clinically 
relevant and had been shown to be associated with disease i.e. 
CAIS/PAIS/DMD/prostate cancer. 
Among the previously reported mutations, the Q28X (X=Stop codon) was 
detected in two girls with Duchene muscular dystrophy (DMD) (Katayama et al., 
2006). In this present study we identified the same mutation in one unaffected 
male 'b'.  
A T82A deletion was previously reported in a CAIS female (Philibert et al., 
2010). In this study we identified the mutation at the same position 82 in control 
female ‘D’ where Threonine was substituted to Arginine. 
Similarly the E155X mutation was found previously in two CAIS females 
(Copelli et al., 1999). In this study we found a mutation at the same position 155 
but E was converted into G (E155G) in two members of the family; one was 
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MAIS affected male 'C' and the other was control male 'a'. A previous study 
identified S221fs (frame shift), a single nt deletion leading to a stop at codon 226 
in one CAIS female (Audi et al. 2010). In this present study, we found a mutation 
in the MAIS affected male 'K' in which S (serine) is substituted to F 
(phenylalanine) at the same position 221. Additionally a Y225X mutation was 
found in a CAIS female in an earlier study (Hannema et al., 2004). We similarly 
found a mutation at the same position in an unaffected female 'c' but with Y being 
substituted with C (Y225C).  
Upon conducting a more thorough investigation we also found similar mutations 
to be associated with disease state. Almost all of the previously identified 
mutations were correlated with, and have been demonstrated to play a significant 
role in disease development. For example, E289X was found in one previous 
study in a CAIS female (Holterhus et al., 2003). In this study a mutation was 
found at the same position E289G in affected male ‘C.  
Similarly the P380R mutation was detected in one PAIS male and one CAIS 
female, where a 11bp duplication was the result of a mutation at the position 
P380fs (Audi et al., 2010, Philibert et al., 2010). In the present study, a mutation 
was identified at the same position; however, the amino acid 'P' was substituted 
with 'L' at position P380L in the one control female ‘D’. Despite the described 
importance of the mutation at this position we did not identify an associated 11 bp 
duplication. Given that the amino acid change was not the same as described in 
the literature; it is conceivable that such a mutant could be a naturally occurring 
variant.  
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T440P was previously reported in one male prostate cancer patient (Steinkamp et 
al., 2009). In this present study a T440A was found in one unaffected female ‘F, 
once again indicating the same position for the mutation. Interestingly a E442X 
mutation was detected in two previous studies where the mutation was reported in 
CAIS females (Luo et al., 2011, Sun et al., 2010). In contrast, in the present study 
a E442K mutation was identified in one unaffected male ‘b’.  
Along similar lines a Q445R was reported in a previous study of one CAIS female 
(Gottlieb et al., 1999b). We found the same mutation in the MAIS affected male, 
‘C’.  G456S mutation was identified in another earlier study in two males, both of 
which had prostate cancer (Steinkamp et al., 2009). In this present study we 
identified G456D in the one MAIS affected male ‘E’. Importantly, another 
mutation, Y481X, was found in three females of which two were CAIS and the 
third who developed liver cancer (Gottlieb et al., 1999b; Hannema et al., 2004; 
Yeh et al., 2007). Similarly, we identified a mutation at position Y481C in one of 
the unrelated female control ‘D’. A Q488 deletion was reported previously in 
three CAIS siblings (Boehmer et al., 2001). In the present study we detected 
Q488R in a single control male ‘a’. Another somatic mutation G525S/D was 
described in two prostate cancer males (Hyytinen et al., 2002), and we similarly 
detected the G525D in unaffected female ‘c’. Since all these mutations were 
described to be disease associated we cannot negate the importance of the 
mutations in this family.  
Since 2004 the number of reported mutations AR gene have been steadily 
increasing (Gottlieb et al., 2012). Some studies have proposed the role of a 
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‘genetic background’ or ‘modifiers’, in varying manifestations of AIS (Yong et 
al., 2003, Gottlieb et al., 2005). The mutations/polymorphisms in the genes 
involved in androgen action might affect the overall response to androgens 
(Gottlieb et al., 2005; Holterhus et al., 1997; Gottlieb et al., 2001). The exposure 
of the foetus to androgens at the embryonic stage has also been suggested to 
account for the variations (Houlston and Peto, 2004). Mutations in the AR gene 
are known to show phenotypic variation in different individuals. Substantial 
variations have been noted in familial cases bearing the same mutation.  
Somatic mutations in the androgen target tissues and androgen responsive organs 
have been proposed to contribute to phenotypic variation in some cases (Gottlieb 
et al., 2005; Holterhus et al., 1997; Gottlieb et al., 2001). However, somatic 
mutations have only been able to explain the phenomenon in a few of the more 
than 25 cases of phenotypic variation reported to date (Gottlieb et al., 2001). In 
one of the study by Holterhus et al., they revealed the presence of a single 
mutation in the AR gene in 4 members of the same family, but with different 
phenotypes (Holterhus et al., 2000).  
In the present study, we identified a total of 30 novel mutations, in which single 
amino acid substitutions were seen. Interestingly, four of the mutations were seen 
in highly conserved residues (aa 224-258) of AF-1 domain of AR lies in exon 1. 
The AF1 domain is of immense importance due to the highly conserved 
hydrophobic nature of the amino acids, and shows complete homology from fish 
to primates, and shows 60-70% reduced functional activity if mutated (Betney and 
McEwan, 2003).  
94 
 
Among the four mutations, one each of the three mutations was present in three 
affected members and one was found in a genetically related unaffected member. 
They were located in this highly conserved AF-1 domain. Importantly, the three 
mutations identified in affected members were novel and of the three affected 
members, two developed MAIS and the third, a female developed breast cancer. 
Analysis revealed mutations at the position T231I and C240R in two affected 
males ('E' and 'I') with MAIS and gynecomastia and a single mutation at position 
V245M were identified in the female ('d') with breast cancer, and a single 
unaffected female 'c' showed mutation at the position Y225C, which was 
previously reported in CAIS female (Hannema et al., 2004). Since, such 
mutations are of high relevance, they all warrant future functional/structural 
studies. All the mutations and their details are given in the Figure 25.  
The number of mutations in MAIS has been increased since 2004 from 7 to 22, 
and these mutations were due to nucleotide substitution. The reason for a 
significant number of missense mutations between aa residue 214 to 511 in the 
MAIS affected males remains a mystery; however, it has been suggested by 
Gottlieb et al., that the missense mutations obtained in this region of NTD have a 
minor effect on the function of AR (Gottlieb et al., 2012). In the present study we 
identified 21, (50%) missense mutations between the aa residues 214 to 511 of 
AR transactivation domain, 12/21 mutations were novel and 9/21 were previous 
described. The majority (11) of the mutations were detected in affected members 
of the family at position T231I, L345P, C240R, Q360R, R386C, L347F, V245M 
and are novel. The remaining four mutations are recurrent mutations occurring at 
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position E289G, Q445R, G456D and S221F. The mutations identified in this 
region provide a strong basis for the MAIS with gynecomastia development in 
males and development of breast cancer in females. Among unaffected 
genetically linked members we found six mutations spanning this region. The 
three detected at position L389P, G326D, P422S were novel and those at position 
T440A, E442K and Y225C were previously reported. , surprisingly, we found 
four mutations at the position A372T, S361G which are novel, and Y481C, 
Q488R are reported mutations in unrelated members, who were also the sexual 
partners of the affected members and were used as controls, however, no genetic 
link can be established, and investigations are required to know their familial 
history and background.  
Only 2 novel mutations were identified at the position W527R and M528V in the 
BC affected female. The remaining 19 novel mutations were found between the 
aa 25 to 213, and among affected members, we found 8 at the position L108P, 
E113K, Q78R, E187G, T105I, E32V, N25S, V132A. Among unaffected 
members, we found 5 mutations at the position P153L, Q72R, Q78R, M191T, 
G173S and the controls also showed 5 mutations at position T82A, Q79R, V33A, 
Q98R and P49L. Mutations spanning from 214 to 511 amino acids in the 
transactivation domain of AR in MAIS patients remain a mystery and is an area of 
intense future research, but at present, it does suggest the importance of exon 1 
alone in asserting the overall modulation effect of the AR (Gottlieb et al., 2012). 
In summary, we have identified several novel and recurrent mutations in the NTD 
of androgen receptor gene in the affected members of the family. Detailed 
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functional studies are now necessary to verify the mechanism and the 
pathogenicity of the novel mutations and are the basis of intense future research 
endeavors.  
An important feature to arise from the genetic study of this family is the apparent 
genetic heterogeneity observed in AR exon 1. A study in 1997 was one of the first 
to first to appreciate the role of somatic mutation in the AR in causing PAIS 
(Holterhus et al., 1997).  In this study the authors found one of the previously 
reported mutations L172X abrogated AR expression and was the main reason for 
the observed androgen insensitivity. However in another study by the same group 
they identified the same mutation but patients this time presented with the PAIS 
phenotype. Functional assay of androgen binding further revealed that cells of 
PAIS patients has measurable androgen binding activity, despite the presence of 
stop codon mutation L172X. While looking for the cause of such phenomenon it 
was later discovered that the mutation was inherited from the patient’s mother, 
however the same mutation had been acquired in the form of a 
mixed/heterogenous population (Holterhus et al., 1999). In a study utilizing 
PBMCs and GSF the authors found that phenotypic variability caused by somatic 
mosaicism could also occur as a result of denovo post-zygotic forward mutations 
in AR gene (Hirot et al, 1998). Currently only five cases of variable AIS 
phenotypes are confirmed to be caused by somatic mosaicism (Holterhus et al., 
1999). 
The somatic mosaicism of mutant and wild-type AR allele is a prime molecular 
factor of in vivo androgen action and the associated somatic mosaicism identified 
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in the present study could be the main cause of MAIS in members of the present 
family.  
Due to somatic mutations variable expression of the AR has been observed in 
prostate cancer and is a primary source of variable expressivity.  Somatic changes 
are common in cancer, but recent data indicates that many other diseases could 
also be caused by somatic mutations (Frank and Nowak, 2004). Recent literature 
has highlighted the role of somatic mutations in primary immune deficiency, 
neurofibromatosis, secondary hypertension and prostate cancer (Beuschlein et al., 
2013; Tsujimoto et al., 2004 and Ackerman, 1998).  Results in many of these 
studies have been driven by next generation sequencing. Therefore to investigate 
AR mutations in this family further and to determine the role played by somatic 
mosaicism will require more in depth investigation of the phenotypic-genotypic 
relationship in vivo/ in vitro. 
Androgen receptor and breast cancer 
Among all the family members right arm including affected and presently 
unaffected members revealed longest length of CAG repeat. Long poly Q stretch 
was 25 in numbers were identified in breast cancer affected female (d) and in 
addition longer poly Q were identified in her sibling (b,c), indicating possible 
chances of these subject to develop breast cancer and MAIS with gynecomytia in 
future. Similarly longer GGN repeat length were identified in female affected with 
breast cancer and both of her sibling. Four novel mutations were identified in the 
breast cancer affected female at the positions V132A (GTC→GCC), V245M 
(GTG→ATG), W527R (TGG→CGG) and M528V (ATG→GTG); however none 
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of the mutations were previously reported. Among all the risk factors family 
history is considered as top most risk factors in breast cancer patients, those 
members showing increased length of CAG repeat have higher chances of 
developing breast cancer. A recent review by Rajender et al., 2011 described over 
10 studies which found association of longer CAG repeat with breast cancer, 
however there are some studies which could not found such and 2 studies which 
found inverse correlation of CAG repeat length with breast cancer. In addition 
mutations in the Androgen receptor could compliment increased CAG repeat 
affect and may exacerbate the breast cancer development, this could possibly be 
due to reduced androgen receptor transactivation activity lowering androgen: 
estrogen balance and promoting pathogenesis 
6. CONCLUSIONS 
The family included in the study is unique and interesting as there is segregation 
of two diseases in two separate arms of the family. MAIS/gynecomastia affected 
males were present in one arm of the family and females affected with breast 
cancer were present in another arm of the family. Clinical features and symptoms 
of affected males typically showed gynecomastia in all affected male members of 
the family.   
We decided to analyze the whole androgen receptor gene because it is the leading 
source of AIS. On the basis of clinical symptoms, we grouped the family into 
three groups: affected, unaffected and control members. We analyzed all the 
exons from 1-8 of androgen receptor gene and found substitution mutations 
throughout the exon 1 of AR gene in all three groups of family members. We 
extended our study and analyzed the remaining exons 2 to 8, however, all the 
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exons from 2 to 8 were found totally wild type and well conserved in all the 16 
members of the family.  
In exon 1, we initially focused on the highly polymorphic CAG repeat length, as 
an extension of CAG repetition is involved in different kinds of diseases including 
AIS. We were expecting the expansion of CAG repeat length in affected members 
of the family especially males with MAIS and gynecomastia, as gynecomastia is 
one of the symptoms associated with the neurodegenerative disease 'Kennedys 
disease' in which trinucleotide repeat of CAG extend more than 40 repeats. 
Surprisingly, we did not find an increased expansion of the CAG repeats in these 
MAIS affected males of the family. 
On further analysis, we found generation specific patterns of (CAG)n length. In 
the second generation, we found shorter CAG repeat length in a single unaffected 
male. Also in the third generation all affected males showed shorter CAG repeat 
length. This led us to assume that shorter CAG repeat length had been transferred 
from second generation. However when we analyzed the fourth generation 
members we were surprised to discover longer CAG repeat lengths in all affected 
members of the fourth generation. Interestingly, unaffected males and females of 
the fourth generation also showed longer CAG repeat. Based on these 
observations we conclude an indeterminate association of CAG repeat length with 
breast cancer and MAIS with gynecomastia within affected members of this 
family. However there does appear to be some generational modulation of the AR 
gene with respect to the CAG repeat sequence.  
Secondly, we focused on another polymorphic region of the AR gene i.e., GGN 
repeat length which varies from 10 to 30 in many population groups. In the  
second, third and fourth generation members, we found shorter GGN repeats 
except one control female in which we found longer a GGN repeat. Since all three 
groups of the family (viz. the affected, unaffected and controls) had shorter GGN 
repeat lengths we also conclude an indeterminate association of GGN repeat 
length with breast cancer and MAIS in this family. 
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The final focus was that of the point mutations which were identified throughout 
exon 1 of AR gene in all the members of the family except one control female 
who is completely wild type. In total 43 missense mutation were identified in the 
trans-activation domain of AR gene: 30 unreported (novel) mutations as well as 
13 recurrent (previously reported) mutations. Seventeen novel and 5 recurrent 
mutations were identified in the affected group; 8 novel and 5 reported mutations, 
including one premature stop codon mutation were identified in the unaffected 
normal group and 7 novel and 4 reported mutations were found in the control 
group. Of the above-mentioned mutations, three novel mutations and one 
recurrent mutation were identified in the activation function-1 (AF-1) domain of 
exon 1 in 3 affected members (2 males and one female) and in one genetically 
related unaffected female member of the family. Although these 3 mutations of 
the AF-1 domain have not been previously identified and reported in patients, 
previous in-vitro studies have carried out using mutations specific for this regions 
and it was concluded that mutations of this AF-1 region could reduce the AR 
transactivation activity by 60-70%. 
The reason for a significant number of missense mutations between aa 214 to 511 
causing MAIS remains a mystery it has been suggested that missense mutations in 
this part of exon 1 have a slight effect on overall AR function (Gottlieb et al., 
2012).  In this study family we identified 21, (50%) missense mutations between 
the aa residues 214 to 511 of AR transactivation domain. The majority (11) 
mutations were found in affected members of the family and we conclude that the 
mutations identified in this region could affect the AR function and might be a 
strong cause for the diseases observed in this family. Since mutations were also 
detected in unaffected genetically linked members in this region, it is reasonable 
to speculate that these unaffected family members may be afflicted with an AR 
related disease in the future.  
Regarding the identification of mutations in the single breast cancer affected 
female in the breast cancer arm, we conclude that changes in this regions may 
lead to altered modulation of transactivation function of androgen receptor, 
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changing its overall activity and thereby playing a role in breast cancer 
development. 
 
 
 
 
 
 
6.1 FUTURE DIRECTION 
The 43 different mutations spread along the entire transactivation domain of the 
exon 1 of AR gene are the defining feature of this family. The point mutations 
presented needs to be explored for their functional relevance and further studies 
are required to confirm if such mutations have an effect on the overall 
transactivation function and the resultant signaling mechanism of androgen 
receptor thereby changing the pathogenicity and severity of the disease.  
Mutations identified in AF-1 domain of exon 1 of androgen receptor seems to be 
of major concern, followed by those identified within the aa 214-511 region, 
mainly in affected males with MAIS/gynecomastia and the female with breast 
cancer. Investigations are required to understand the population as well as familial 
history and background of the unrelated control members of the family which also 
showed few mutations in the exon 1 of AR. 
102 
 
 
 
 
 
 
 
 
Appendix A 
 
103 
 
 
 
104 
 
Appendix B 
Sucrose Triton-X Lysis buffer 
10 ml 1 M Tris HCl pH 8 
5 ml 1 M MgCl2 
10 ml Triton X-100 
Makeup to 1000 ml with distilled water. Autoclave and store at 4 ˚C. 
Add 109.5 g sucrose just before use. Make fresh buffer for each use. 
T20 E5 (pH 8) 
20 mM Tris HCl 
5 mM EDTA 
Autoclave and store at room temperature. 
Saturated NaCl 
40 g NaCl to 100 ml sterile water until completely saturated. 
Store at room temperature. 
Proteinase K mix 
10% SDS 
0.5 M EDTA 
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10 mg /ml proteinase K: add 50 ml sterile water to bottle containing  
500 mg. Aliquot and freeze. 
TBE (10X Stock solution) 
108 g Tris base 
55 g Boric acid 
40 ml 0.5 M EDTA pH 8 
Makeup to 1 litre with distilled water. 
PBS (Phosphate buffered Saline) 
8 g NaCl 
0.2 g KCl 
1.44 g Na2 HPO4 
0.24 g KH2 PO4 
Dissolve in 800 ml of distilled water. Adjust pH to 7.4 Make up to 1000 
ml, sterilize by autoclaving and store at room temperature. 
10X TBE buffer 
108 g Tris base 
55 g Boric acid 
9.3 g EDTA 
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Adjust volume to 1000 ml with distilled water. Sterilize by autoclaving 
and store at room temperature. 
1X TBE buffer 
100 ml 10 X TBE buffer 
900 ml distilled water 
Mix thoroughly. 
Agarose gel, 0.7% or 1% 
0.7 g (0.7%) or 1 g (1%) agarose 
100 ml 1X TBE buffer 
Dissolve agarose in 1X TBE buffer by heating in a microwave oven for 3 
minutes, shake occasionally, until all the agarose particles are completely 
dissolved. Care must be taken that the high percentage gels do not boil 
over. Cool to 50 ˚C. Add 6 µl mg/ml Ethidium bromide and mix it well. 
Pour into a prepared casting tray and allow to solidify completely at room 
temperature. 
0.5M Ethylene diamine tetraacetic acid (EDTA) (pH 8) 
18.61 g Ethylene diamine tetra acidic acid 
80 ml Distilled water 
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Stir vigorously on a magnetic stirrer. Adjust pH to 8 with 10 M NaOH. 
Adjust volume to 100 ml distilled water. Sterilize by autoclaving and store 
at room temperature. 
Luria-Bertani (LB) medium  
10 g Bacto Tryptone 
5 g Yeast extract 
10 g NaCl 
Adjust volume 1000 ml with distilled water. Sterilize by autoclaving and 
store at 4 ˚C. 
LB agar plates with ampicillin 
10 g Bacto Tryptone 
5 g Yeast extract 
10 g NaCl 
15 g Bacteriological agar 
Adjust volume to 1000 ml with distilled water. Sterilize by autoclaving. 
Allow the medium to cool to 50 ˚C before adding ampicillin to a final 
concentration of 50 mg/ml. Pour 30-35 ml of medium into 85 mm 
petridishes. Let the agar solidify completely at room temperature and store 
at 4 ˚C for up to 1 month. 
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LB plates with ampicillin/IPTG/X-gal 
Make the LB plates with ampicillin as above, then supplement with 100 µl 
of 100 mM IPTG and 20 µl of 50 mg/ml X-gal pour separately, and spread 
over the LB ampicillin plate and allow to absorb for 30 mins at 37 ˚C prior 
to use. 
SOC medium 100 ml (pH-7) 
2 g Bacto®- Tryptone 
0.5 g Bacto®-yeast extract 
1 ml 1 M NaCl 
0.25 ml 1 M KCl 
1 ml 2 M Mg
2+
 stock, filter sterilized 
1 ml 2M glucose, filter sterilized 
Add; Bacto tryptone, Bacto-yeast extract, NaCl and KCl to 97 ml distilled 
water. Stir to dissolve autoclave and cool to room temperature. Add 2 M 
stock Mg
2+ 
and 2 M glucose, each to a final concentration of 20 mM. 
Bring to 100 ml with sterile, distilled water. The final pH should be 7. 
2 M Mg
2+
 Stock 
20.33 g MgCl2. 6H2O 
24.65 g MgSO4. 7H2O  
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Add distilled water to 100 ml. Filter sterilize. 
Psi broth (pH 7.6) 
5 g Bacto yeast extract 
20 g Bacto tryptone 
5 g Magnesium Sulfate 
Adjust volume to 1000 ml with distilled water. 
Sterilize by autoclaving. 
Tfb I (pH 5.8) 
0.588 g Potassium Acetate (30 mM) 
2.42 g Rubidium Chloride (100 mM) 
0.294 g Calcium Chloride (10 mM) 
2 g Magnesium Chloride (50mM) 
30 ml Glycerol (15% v/v) 
Adjust the volume to 200 ml with distilled water. Filter sterilize. 
Tfb II (pH 6.5) 
0.21 g M OPS (10 mM) 
1.1 g Calcium Chloride (75 mM) 
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0.121 g Rubidium Chloride (10 mM) 
15 ml Glycerol (15% v/v) 
Adjust the volume to 100 ml with distilled water. Filter and sterilize. 
6X Loading dye (Promega) 
15% Ficoll ® 400  
0.03% Bromo-phenol blue 
0.03% Xylene Cyanol FF  
0.4% Orange G  
10 mM Tris HCl (pH 7.5) 
50 mM EDTA. 
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Table 3: Ligation reaction component 
Reaction component Standard reaction Positive control Background control 
2X rapid ligation buffer 5 µl 5 µl 5 µl 
pGEM®-T easy 
 vectors (50 ng) 
1 µl 1 µl 1 µl 
PCR product X µl* - - 
Control insert DNA - 2 µl - 
T4 DNA ligase  
(3 Weiss U/µl) 
1 µl 1 µl 1 µl 
Nucleus free water to a 
final volume of 
 
10 µl 
 
10 µl 
 
10 µl 
 
* Molar ratio of (3:1) PCR product (insert): vector may require optimization. 
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Table 4: Restriction digestion and mapping of purified plasmid DNA with 
Fast digest enzyme Not I 
Reaction component  Uncut 
10 X Fast digest buffer 1 µl - 
Fast digest enzyme Not I 0.5 µl - 
DNA Up to 1 µg 2 µl 
Nuclease free water to a 
final volume of 
 
10 µl 
 
10 µl 
 
Incubate at 37 ˚C for 50 to 60 mins. 
Thermal inactivation of Fast digest enzyme, Not I at 80 ˚C for 5 mins. 
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Appendix C 
 
 
 
 
Figure 13: The p
GEM®
- T Easy Vector Map: pGEM®-T easy vector 3015bp in 
size and it is a linearized vector with a single 3`-terminal thymidine (T) at both 
ends. The T- overhangs at the insertion sites greatly improve the efficiency of 
ligation of PCR products by preventing re-circularization of the vector and 
providing a compatible overhang for PCR products, generated by certain thermo 
stable polymerases. The pGEM®-T easy vectors are high copy number vectors 
containing T7 and SP6 RNA polymerase promoters flanking a multiple cloning 
region within the α- peptide coding region of the enzyme β-galactosidase. 
Insertional inactivation of the α- peptide allows identification of recombinants by 
blue/white screening on LB agar plates with ampicillin. These vectors contained 
numerous restriction enzyme sites within the multiple cloning regions.  
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 Figure 14: Sequence and multiple cloning site of the pGEM
®
-T easy vector. The 
top strand shown corresponds to the RNA synthesized by T7 RNA polymerase. 
The bottom strand corresponds to the RNA synthesized by SP6 polymerase.  
 
 
 
 
Sequence and multiple cloning site 
of p
GEM
 -T easy vector  
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Figure 71: The chart representing the different properties of amino acid. 
Adopted from (http://www.geneinfinity.org/sp/sp_aaprops.html) 
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Appendix D 
 
Figure 26: Electropherogram showing L 108 P and E 113 K novel mutations in 
exon 1 of AR gene in MAIS affected male ‘C’. Where L = leucine, P = Proline 
and E = Glutamic acid, K = Lysine. 
 
Figure 27: Electropherogram showing T 231 I novel mutation in exon 1 of AR 
gene in MAIS affected male ‘E’. Where T = Threonine and I = Isoleucine.  
ACC ATC 
CTG GAA  
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Figure 28: Electropherogram showing Q 78 R novel mutation in exon 1 of AR 
gene in MAIS affected male ‘H’. Where Q = Glutamine and R = Arginine.  
 
 
Figure 29: Electropherogram showing E 187 G novel mutation in exon 1 of AR 
gene in MAIS affected male ‘H’. Where E = Glutamic acid and G = Glycine. 
GGG GAG 
CAG  CGG 
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Figure 30: Electropherogram showing L 345 P novel mutation in exon 1 of AR 
gene in MAIS affected male ‘H’. Where L = Leucine and P = Proline.  
 
 
Figure 31: Electropherogram showing T 105 I novel mutation in exon 1 of AR 
gene in MAIS affected male ‘I’. Where T = Threonine and I = Isoleucine.  
  
ACA ATA 
CTG CCG 
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Figure 32: Electropherogram showing C 240 R novel mutation in exon 1 of AR 
gene in MAIS affected male ‘I’ Where C = Cysteine and R = Arginine.  
 
Figure 33: Electropherogram showing E 32 V novel mutation in exon 1 of AR 
gene in MAIS affected male ‘K’. Where E = Glutamic acid and V = Valine.  
GAA  GTA 
C 240 R 
TGT CGT 
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Figure 34: Electropherogram showing Q 360 R novel mutation in exon 1 of AR 
gene in MAIS affected male ‘K’ Where Q = Glutamine and R = Arginine. 
 
 
Figure 35: Electropherogram showing R 386 C novel mutation in exon 1 of AR 
gene in MAIS affected male ‘K’. Where R = Arginine and C = Cysteine. 
CG TGC 
CAG CGG 
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Figure 36: Electropherogram showing N 25 S novel mutation exon 1 of AR gene 
in MAIS affected male ‘L’. Where N = Aspargine and S = Serine. 
 
 
Figure 37: Electropherogram showing L 347 F novel mutation in exon 1 of AR 
gene in MAIS affected male ‘L’ Where L = Leucine and F = Phenylalanine. 
CTC TTC 
    AGT AAT  
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Figure 38: Electropherogram showing novel mutation V132A in exon 1 of AR 
gene in BC affected female ‘d’. Where V = Valine and A = Alanine. 
 
 
Figure 39: Electropherogram showing the novel mutation V 245 M in exon 1 of 
AR gene in BC affected female ‘d’, where V = Valine and M = Methionine. 
Start codon 
GTG 
GTC GCC 
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Figure 40: Electropherogram showing W 527 R novel mutation in exon 1 of AR 
gene in BC affected female ‘d’. Where W = Tryptone and R = Arginine. 
 
 
 Figure 41: Electropherogram showing M 528 V novel mutation in exon 1 of AR 
gene in BC affected female ‘d’. Where M = Methionine and V = Valine.  
ATG GTG 
TGG CGG 
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Figure 42: Electropherogram showing E 155 G reported mutation in exon 1 of 
AR gene in MAIS affected male ‘C’. Where E = Glutamic acid and G = Glycine.  
 
 
 
Figure 43: Electropherogram showing E 289 G reported mutation in exon 1 of 
AR gene in MAIS affected male ‘C’. Where E = Glutamic acid and G = Glysine. 
  
GGA GAA 
  GAG  GGG 
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Figure 44: Electropherogram showing Q 445 R reported mutation in exon 1 of 
AR gene in MAIS affected male ‘C’. Where Q = Glutamine and R = Arginine. 
 
 
 
Figure 45: Electropherogram showing the G 456 D reported mutation in exon 1 
of AR gene in MAIS affected male ‘E’. Where G = Glycine and D = Aspartic 
acid. 
GAT GGT 
CAG CGG 
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Figure 46: Electropherogram showing S 221 F reported mutation in exon 1 of AR 
gene in MAIS affected male ‘K’. Where S = Serine and F = Phenylalanine.  
 
Figure 47: Electropherogram showing P 153 L novel mutation in exon 1 of AR 
gene in unaffected male ‘B’. Where P = Proline and L = Leucine. 
CCG  CTG 
TCC  TT
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Figure 48: Electropherogram showing L 389 P novel mutation in exon 1 of AR 
gene in unaffected male ‘B’. Where L = Leucine and P = Proline. 
 
 
Figure 49: Electropherogram showing M 191 T novel mutation in exon 1 of AR 
gene in unaffected male ‘b’. Where M = Methionine and T = Threonine. 
ATG  ACG 
CTG  CCG 
128 
 
 
Figure 50: Electropherogram showing Q 72 R novel mutation in exon 1 of AR 
gene in unaffected female ‘F’. Where Q = Glutamine and R = Arginine. 
 
 
Figure 51: Electropherogram showing Q 78 R novel mutation in exon 1 of AR 
gene in unaffected female ‘F’. Where Q = Glutamine and R = Arginine. 
CAG  CGG 
CAG  CGG 
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Figure 52: Electropherogram showing G 326 D novel mutation in exon 1 of AR 
gene in unaffected female ‘F’. Where G = Glycine and D = Aspartic acid.  
 
 
 
Figure 53: Electropherogram showing G 173 S novel mutation in exon 1 of AR 
gene in unaffected female ‘c’. Where G = Glycine and S = Serine. 
GGC  AGC 
GGC  GAC 
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Figure 54: Electropherogram showing P 422 S novel mutation in exon 1 of AR 
gene in unaffected female ‘c’. Where P = Proline and S = Serine. 
 
 
 
Figure 55: Electropherogram showing the T 440 A reported mutation in exon 1 
of AR gene in unaffected female ‘F’. Where T = Threonine and A = Alanine.  
GCA ACA 
CCC  TCC 
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Figure 56: Electropherogram showing Q 28 Stop codon, reported mutation in 
exon 1 of AR gene in unaffected male ‘b’. Where Q = glutamine.  
 
 
 
Figure 57: Electropherogram showing the E 442 K reported mutation in exon 1 
of AR gene in unaffected male ‘b’. Where E = Glutamic acid and K = Lysine. 
AAA GAA 
STOP 
Q 28 Stop 
CAG 
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Figure 58: Electropherogram showing the Y 225 C reported mutation in exon 1 
of AR gene in unaffected female ‘c’. Where Y = Tyrosine and C = Cysteine.  
 
 
 
Figure 59: Electropherogram showing the G 525 D reported mutation in exon 1 
of AR gene in unaffected female ‘c’. Where G = Glycine and D = Aspartic acid. 
GAC GGC 
TGC TAC 
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Figure 60: Electropherogram showing T 82 A novel mutation in exon 1 of AR 
gene in control female ‘D’. Where T = Threonine and A = Alanine.  
 
 
 
Figure 61: Electropherogram showing Q 79 R novel mutation in exon 1 of AR 
gene in control female ‘G’. Where Q = Glutamine and R = Arginine.  
CAG CGG 
ACT GCT 
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Figure 62: Electropherogram showing A 372 T novel mutation in exon 1 of AR 
gene in control female ‘G’. Where A = Alanine and T = Threonine.  
 
 
 
 
Figure 63: Electropherogram showing V 33 A novel mutation in exon 1 of AR 
gene in control female ‘J’. Where V = Valine and A = Alanine. 
GTG  GCG 
GCC ACC 
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Figure 64: Electropherogram showing Q 98 R novel mutation in exon 1 of AR 
gene in control female ‘J’. Where Q = Glutamine and R = Arginine. 
 
 
 
Figure 65: Electropherogram showing P 49 L novel mutation in exon 1 of AR 
gene in control male ‘a’. Where P = Proline and L = Leucine. 
CCT  CTT 
CAA CGA 
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Figure 66: Electropherogram showing Q 79 R novel mutation in exon 1 of AR 
gene in control male ‘a’. Where Q = Glutamine and R = Arginine. 
 
Figure 67: Electropherogram showing S 361 G novel mutation in exon 1 of AR 
gene in control male ‘a’. Where S = Serine and G = Glycine. 
AGT GGT 
CAG CGG 
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Figure 68: Electropherogram showing the Y 481 C reported mutation in exon 1 
of AR gene in control female ‘D’. Where Y = Tyrosine and C = Cysteine. 
 
 
 
Figure 69: Electropherogram showing the Q 488 R reported mutation in exon 1 
of AR gene in the control male ‘a’. Where Q = Glutamine and R = Arginine.  
CGG CAG 
TGC TAC 
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Figure 70: Electropherogram showing the E 155 G reported mutation in exon 1 
of AR gene in the control male ‘a’. Where E = Glutamic acid and G = Glycine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GGG GAG 
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